

RISOP, a Reference-Assisted Approach for Enhanced Identification of Oxidized Phospholipids

Zixing Chen[†], Andrew Erickson[†], Natalie Ito[†], Xiaoai Zhao^{†#^}*

[†]Department of Comparative Medicine, Yale School of Medicine, New Haven, Connecticut 06510, USA.

[#]Yale Center for Molecular and Systems Metabolism, Yale School of Medicine, New Haven, Connecticut 06510, USA.

[^]Wu Tsai Institute, Yale School of Medicine, New Haven, Connecticut 06510, USA.

*Correspondence:

Xiaoai Zhao

Yale School of Medicine

New Haven, Connecticut 06510, USA.

xiaoai.zhao@yale.edu

1 **ABSTRACT**

2 Oxidized phospholipids (OxPLs) play critical roles in inflammation, ferroptosis, and other
3 oxidative stress-associated processes, yet their systematic characterization in biological
4 systems remains a major analytical challenge owing to their low abundance and vast structural
5 diversity. Here we report RISOP (Reference-Assisted Identification of Sample-specific Oxidized
6 Phospholipids), an untargeted LC-MS/MS workflow that leverages chemically enriched OxPL
7 reference pools to substantially improve OxPL annotation. Reference pools encompassing
8 diverse oxidative modifications and a wide abundance range were experimentally generated
9 using Fenton reaction and H₂O₂ treatment, providing broad coverage of OxPLs. Reference-
10 assisted integrative analysis yielded a more than twofold increase in identified OxPL species in
11 biological samples under elevated oxidative stress, as demonstrated in ML210-treated cells, a
12 model of ferroptotic stress. We further show that the widely used BODIPY C11 lipid peroxidation
13 probe captures cellular oxidative burden in only a subset of OxPLs identified by RISOP,
14 highlighting the importance of untargeted, comprehensive OxPL profiling. Overall, RISOP
15 provides a versatile platform readily applicable to other classes of oxidized complex lipids for
16 comprehensive characterization in physiological and pathological contexts.

17

18 **INTRODUCTION**

19 Oxidized lipids are a structurally diverse group of molecules produced by chemical or enzymatic
20 oxidation of lipids.¹ They can be broadly classified into oxidized free fatty acids (oxylipins) and
21 oxidized complex lipids, including oxidized phospholipids (OxPLs) and glycerol lipids.¹⁻³ Among
22 oxidized complex lipids, OxPLs constitute one of the most structurally diverse classes of
23 oxidized lipids in biological systems.⁴ OxPLs can be formed through lipid peroxidation, a free
24 radical chain reaction consisting of initiation, propagation, and termination steps.^{5, 6} During
25 initiation, reactive radicals abstract hydrogen atoms from the fatty acyl chains of phospholipids
26 to form lipid radicals (L•). These lipid radicals can react with oxygen to generate lipid peroxy
27 radicals (LOO•), which propagate the reaction by abstracting hydrogen atoms from neighboring
28 lipids, producing lipid hydroperoxides (LOOH) and new lipid radicals. The resulting LOOH can
29 undergo rearrangement, truncation, or further modification, generating a variety of OxPL species
30 with hydroxy (<OH>), hydroperoxy (<OOH>), carboxy (<COOH>) or keto (<oxo>
31 modifications.^{5, 6}

32

33 To evaluate lipid peroxidation in biological systems, several cellular assays have been
34 developed that detect intermediates formed during lipid peroxidation. For example, BODIPY C11

35 reacts with lipid radicals,⁷ whereas Liperfluo detects lipid hydroperoxides (LOOH).⁸ In addition,
36 secondary breakdown products from LOOH such as 4-hydroxynonenal (4-HNE) and
37 malondialdehyde (MDA) can be detected by antibody-based assays.^{9, 10} However, these
38 methods only provide proxy measures of overall lipid peroxidation that do not distinguish the
39 contribution from each pool of oxidized lipids (e.g., oxylipins vs. OxPLs). Furthermore, these
40 assays do not provide identification of the oxidized lipids themselves, missing key information
41 about lipid class, the exact side chain(s) that were oxidized, and the types of oxidative
42 modifications, all of which are critical in understanding the diverse functional roles of OxPLs in
43 biological contexts.

44
45 OxPLs have been implicated in biological processes including inflammation,^{6, 11, 12} autophagy,¹³
46 and cell death pathways¹⁴⁻¹⁶ that are closely associated with cardiovascular diseases,¹⁷⁻¹⁹
47 neurodegenerative diseases^{20, 21} and aging.^{22, 23} Mass spectrometry-based approaches remain
48 the gold standard in analyzing OxPLs.²⁴ However, the extremely low abundance and extensive
49 chemical diversity pose significant challenges for detection and identification of OxPLs.
50 Moreover, while robust targeted lipidomics approaches have been widely used in the analytical
51 studies of oxylipins,^{25, 26} a similar workflow cannot be readily adopted for OxPL analysis. This is
52 primarily due to the greater structural complexity of OxPLs (>1000 predicted species)²⁷⁻²⁹
53 compared to oxylipins (~100),³⁰ compounded by the lack of authentic chemical standards for
54 most OxPLs.³¹ Although mass spectrometry-based methods for OxPL analysis have been
55 reported,³²⁻³⁶ these approaches are limited by some forms of narrow lipid class coverage,^{32, 36}
56 workflow or instrumentation complexity,^{32, 34, 35} and applicability restricted to cultured cell
57 systems.³³ Collectively, these limitations highlight a critical unmet need in developing a
58 streamlined, untargeted lipidomics strategy capable of comprehensive, high-coverage OxPL
59 detection and identification – one that can ultimately advance our mechanistic understanding of
60 OxPL biology.

61
62 In this study, we developed RISOP (reference-assisted identification of sample-specific oxidized
63 phospholipids). We established a platform for comprehensive and enhanced identification of
64 OxPLs in an untargeted lipidomics workflow. RISOP integrates two complementary
65 components. First, chemically enriched OxPL reference pools that are generated from the same
66 biological matrix using two oxidation reactions provide high-quality tandem mass spectra and
67 retention-time anchors for OxPLs that are otherwise too scarce to be annotated directly.
68 Second, an *in silico* spectral library, predicted from the non-oxidized lipids of each sample,

69 constrains annotation to biologically plausible species and minimizes false annotation. In
70 addition, RISOP does not require modification of instrumentation or separate setup for data
71 acquisition. Moreover, the reference-generation strategy gives RISOP broad applicability and
72 allows it to be extended beyond cultured cell systems. Overall, this approach expands analytical
73 capability in studies of OxPLs, and enables functional investigations of OxPLs in physiology and
74 disease.

75

76 **MATERIALS AND METHODS**

77 **Cell Culture and Preparation for Lipidomics**

78 KP4 cell (passage 15–20) was a generous gift from Dr. Mandar Muzumdar (Yale University).
79 Cells were cultured in 6-well plates in high-glucose Dulbecco's modified Eagle's medium (Gibco,
80 11965-092), supplemented with 10% fetal bovine serum (Gibco, A56708-81) and 1% penicillin
81 streptomycin (Gibco, 15140-122), and maintained in an incubator containing 5% CO₂ at 37 °C.
82 KP4 cells at 70% confluence were washed twice with 2 mL ice-cold phosphate-buffered saline
83 (PBS, Gibco, 10010-023) and scraped into 400 µL of PBS, immediately flash-frozen on dry ice,
84 and stored at –80 °C until use.

85

86 **Preparation of Oxidized Lipid References**

87 Fenton reactions were conducted following a previously reported protocol with some
88 modifications.³⁷ First, 400 µL of cell suspension in PBS from one well of the 6-well plates was
89 thawed on ice. Next, 25 µL of 10 M H₂O₂ (Thermo Fisher Scientific, L14000.AP) and 75 µL of
90 333.33 mM of FeCl₂ (Sigma, 44939-50G) were added to cell suspension for a final concentration
91 of 500 mM of H₂O₂ and 50 mM of FeCl₂. For H₂O₂-only reactions, the same amounts of thawed
92 cell suspension in PBS and H₂O₂ were used, and an additional 75 µL of PBS was used to
93 substitute for FeCl₂ solution. Samples were subsequently incubated at 37 °C in the dark for 0
94 min, 1 min, 20 min, 4 h, 24 h, and 72 h. Following incubation, samples were immediately
95 processed for lipid extraction.

96

97 **Lipid Extraction**

98 Lipids were extracted using a 2-phase, liquid-liquid extraction system – a modified Folch
99 method.³⁸ All samples were randomized prior to extraction. All chemicals used for extraction
100 were LC/MS grade unless otherwise indicated. First, 300 µL of methanol (Fisher chemical,
101 A456-4) containing 0.5 µL of deuterated internal standards (EquiSPLASH® mix, Avanti Polar
102 Lipids, 330731), 0.5 µL of cardiolipin standard (Avanti Polar Lipids, 791108C), 0.5 µL of oleic

103 acid standard (Cayman chemical, 9000432), and 0.1 mg/mL 2,6-Di-tert-butyl-4-methylphenol
104 (BHT, Thermo Fisher Scientific, 112992500) were added to 400 μ L of cell suspension in PBS.
105 The mixture was sonicated for 30 sec in a water bath ultrasonicator (VWR, 97042-960) and then
106 rested on ice for 30 sec, repeated three times. Then 600 μ L of ice-cold chloroform (VWR,
107 BDH83627.400) was added to each sample. The resulting mixture was vortexed at 4 °C for 30
108 min. Phase separation was subsequently achieved by centrifugation at 3,000 RPM for 10 min at
109 4 °C. The lower organic phase was collected and dried under a stream of nitrogen. Dried lipids
110 were then reconstituted in 150 μ L of a 9:1 (v/v) methanol/toluene (Fisher chemical, T290-1)
111 solution for liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis.

112

113 **LC-MS/MS Lipidomics**

114 Lipidomic analysis was conducted in accordance with guidelines of the Lipidomics Standards
115 Initiative (LSI) (<https://lipidomicstandards.org/>), and all lipidomics-related information is included
116 in the accompanying LSI reporting checklist³⁹ (Table S1). LC-MS/MS analysis was performed on
117 a Vanquish UPLC system coupled to an Orbitrap Exploris 120 mass spectrometer (Thermo
118 Fisher Scientific). Samples were randomized prior to analysis. Lipid separation was achieved on
119 a Hypersil GOLD C18 HPLC column (100 mm \times 1 mm, 1.9 μ m, Thermo Fisher Scientific,
120 25002-101030) with a flow rate of 120 μ L/min. The column temperature was maintained at
121 45 °C, and the injection volume was 1.5 μ L. Mobile phase A is composed of 60:40 (v/v)
122 acetonitrile (Fisher chemical, A955-4)/water (Fisher chemical, W6-4), and mobile phase B is
123 composed of 88:10:2 (v/v/v) isopropanol (Fisher chemical, A461-4)/acetonitrile/water. Both
124 mobile phases were supplemented with 0.1% formic acid (Fisher chemical, A117-50) and 7.5
125 mM ammonium acetate (Fisher chemical, 198759). The chromatography gradient was as
126 follows: 0–3 min, 10% B; 3–5 min, 10–43% B; 5–5.1 min, 43–55% B; 5.1–15.1 min, 55–65% B;
127 15.1–21.1 min, 65–85% B; 21.1–23.1 min, 85–100% B; 23.1–28.1 min, 100% B; 28.1–28.2 min,
128 100–10% B; 28.2–31.2 min, 10% B. The expected LC peak width was set to 8 sec. Mass
129 spectra were acquired in both positive and negative ion modes in two different runs using a
130 heated electrospray ionization (HESI) source. The spray voltages were set to 3,500 V and 2,500
131 V for positive and negative modes, respectively. The sheath, auxiliary, and sweep gas flow rates
132 were set to 35, 7, and 0 (arbitrary units), respectively. MS₁ full scans and MS₂ tandem mass
133 spectra were acquired in all samples. For MS₁ full scans, the resolution was set to 120,000, with
134 a scan range of 200–1700 *m/z* and an RF lens of 70%. The microscan number was set to 1,
135 with the automatic gain control (AGC) target set to “Standard” and the maximum injection time
136 set to “Auto.” Data were acquired in profile mode. Precursor ions with intensities greater than

137 2.0×10^4 were selected for fragmentation using Top 4 data-dependent acquisition. MS₂ scans
138 were acquired at a resolution of 30,000 with the auto-extended scan range mode enabled. The
139 isolation window was set at 1.2 *m/z*. Stepwise normalized collision energies of 20%, 30%, and
140 40% were used for fragmentation. The microscan number was set at 1. The automatic gain
141 control (AGC) target was set to "Standard," and the maximum injection time was set to "Auto."
142 Data were acquired in profile mode. A dynamic exclusion of 8.5 s was applied to prevent
143 repeated fragmentation of the same precursor ion. For quality control, a pooled sample was
144 repeatedly injected after every 10 samples throughout the analytical runs, and the coefficient of
145 variation (CV) of internal standard intensities was used to assess the stability of the LC-MS
146 system. Calculated CVs of all internal standards in this study were <6%. Retention time drift
147 was monitored by the retention time of internal standards. Calculated retention time drift was
148 between 0.01–0.03 minutes.

149

150 **Identification of Non-Oxidized Lipids Using MS-DIAL**

151 Lipidomics data files were processed using MS-DIAL software (version 5.5.250221) for the
152 identification of non-oxidized lipids. The analysis was conducted within the software's lipidomics
153 framework. Centroid data type was selected for both MS₁ and MS₂. The MS₁ and MS₂ tolerance
154 were set at 0.01 and 0.025 Da, respectively. The minimum peak height was set to 1000
155 amplitude, and the mass slice width was set to 0.05 Da. Linear weighted moving average was
156 used as the smoothing method, with a smoothing level of 3 scans and minimum peak width of 5
157 scans. The non-oxidized lipids were identified using the built-in default spectral library
158 (Msp20250218112233_NCDK_conventional_converted_dev_1) in MS-DIAL. For lipid
159 identification, thresholds for dot product score were set at 150, weighted dot product score was
160 set at 150, reverse dot product score was set at 500, matched spectrum percentage was set at
161 0%, and minimum number of matched spectra was set at 1. HCOONH₄ was selected as the
162 solvent type for searching, as we observed that phospholipids with [M+HCOO]⁻ adducts have
163 higher intensities than those with [M+CH₃COO]⁻ adducts during ionization, likely due to the
164 presence of formic acid in mobile phases.^{40, 41} For positive mode, [M+H]⁺, [M+NH₄]⁺, [M+Na]⁺,
165 and [M+H-H₂O]⁺ adducts were selected for annotation. For negative mode, the [M-H]⁻,
166 [M+HCOO]⁻, and [M+CH₃COO]⁻ adducts were selected for annotation. Samples were aligned to
167 the pooled sample, with a retention time tolerance of 0.1 min and MS₁ tolerance of 0.015 Da. To
168 minimize misannotation, all identified lipids were manually validated by inspecting the tandem
169 mass spectra for fragment ions diagnostic of the assigned headgroup and fatty acyl chains (in

170 the accompanying LSI reporting checklist [Table S1] and Table S2). All non-oxidized lipids were
171 reported at the molecular species level (see “*Lipidomics Nomenclature*” below).

172

173 **Construction of Sample-specific OxPL Spectral Library**

174 Sample-specific OxPL spectral library was constructed from identified lipids of the following
175 classes: phosphatidylcholine (PC), ether-linked phosphatidylcholine (PC-O),
176 phosphatidylethanolamine (PE), ether-linked phosphatidylethanolamine (EtherPE-O), ether-
177 linked phosphatidylethanolamine (EtherPE-P), phosphatidylglycerol (PG), phosphatidylinositol
178 (PI), phosphatidylserine (PS), lysophosphatidylcholine (LPC), ether-linked
179 lysophosphatidylcholine (EtherLPC-O), lysophosphatidylethanolamine (LPE), and ether-linked
180 lysophosphatidylethanolamine (EtherLPE-O). The list of identified non-oxidized lipids with their
181 lipid classes was imported into LPPtiger 2 for *in silico* oxidation, with a maximum number of
182 modification sites set at 3, and the maximum number of O, OH, oxo, OOH, and epoxy
183 modifications set at 4, 2, 1, 1, and 0, respectively. The resulting theoretical tandem mass
184 spectral library, exported from LPPtiger 2 in JSON format, was organized to include the
185 diagnostic ions corresponding to oxidized lipid precursor ion, headgroup fragment, unoxidized
186 fatty acyl chain(s), and oxidized fatty acyl chain(s) of the OxPLs, and converted to MSP format
187 using a custom script in R (version 4.5.0). For example, for PC(16:0_16:1<OH>), the following
188 diagnostic ions are included: *m/z* 224.0682-headgroup, *m/z* 255.2330-unoxidized side chain
189 (16:0), *m/z* 269.2122-oxidized side chain (16:1<OH>), *m/z* 251.2017-oxidized side chain with
190 H₂O loss (16:1<OH> – H₂O), *m/z* 792.5396-precursor (PC(16:0_16:1<OH>) with [M+HCOO]⁻
191 adduct), and *m/z* 732.5185-precursor with neutral loss of CH₃COOH.

192

193 **Identification of OxPLs in Fenton and H₂O₂-only Oxidized Lipid References**

194 OxPL identification in separate Fenton and H₂O₂-only references: Lipidomics data files obtained
195 from Fenton or H₂O₂-only reactions were analyzed separately in MS-DIAL. Parameters used
196 were identical to those described above for non-oxidized lipids, except that the sample-specific
197 OxPL spectral library constructed above was used in place of the default spectral library. All
198 identified oxidized lipids were manually validated by inspecting the tandem mass spectra for
199 fragment ions diagnostic of the assigned headgroup and fatty acyl chain(s) (Table S1 and Table
200 S2). OxPLs were reported at the molecular species level when both fatty acyl chains were
201 identified in the spectra and at the species level when only one fatty acyl chain was identified.
202 Only OxPLs that were detected in at least three samples across different time points of each
203 reference type were kept. To minimize false annotation of background noise, coefficient of

204 variation (CV)-based filtering was applied separately to non-oxidized lipids and OxPLs. Non-
205 oxidized lipids were retained if they had a CV <20% for at least one treatment time point
206 (including 0 h) in either Fenton or H₂O₂-only references. OxPLs were retained if they had a CV
207 <20% for at least one treatment time point (excluding 0 h) in either reference set. Calculation of
208 CV values is described below in “*Quantification of Non-oxidized and Oxidized Lipids in Fenton*
209 *Reaction and H₂O₂-only Oxidized Lipid References*”. Identified lipids from the 2 separate
210 analyses after the removal of potential in-source fragmentation (ISF) products (see “*Hydrogen-*
211 *based Kendrick Mass Defect (H-KMD) Analysis*” below) were used to generate the Venn
212 diagram in Figure 2B.

213
214 OxPL identification by combined analysis of Fenton and H₂O₂-only references: Lipidomics data
215 files from the Fenton reactions, H₂O₂-only reactions, and ML210-treated samples (see “*ML210*
216 *treatment*” below) were analyzed together in MS-DIAL for integrative analysis and identification.
217 This approach was used to ensure consistent OxPL annotation based on retention time and *m/z*
218 matching across biological samples and oxidized lipid references. The MS-DIAL settings and
219 lipid validation steps were identical to those described above for OxPL identification. This
220 workflow provides a list of OxPLs detected in Fenton reaction and H₂O₂-only reference samples.
221 Only OxPLs that were detected in at least three samples across different time points of each
222 reference type were kept. Similarly, CV-based filtering was applied separately to non-oxidized
223 lipids and OxPLs. Non-oxidized lipids were retained if they had a CV <20% for at least one
224 treatment time point (including 0 h) in either Fenton or H₂O₂-only references. OxPLs were
225 retained if they had a CV <20% for at least one treatment time point (excluding 0 h) in either
226 reference set. The resulting filtered OxPLs from the Fenton and H₂O₂-only references after the
227 removal of potential ISF products were used to generate the Venn diagram in Figure 3A.

228

229 **Hydrogen-based Kendrick Mass Defect (H-KMD) Analysis**

230 H-KMD analysis was performed to visualize the differences of retention time and H-KMD
231 between oxidized phospholipids and their corresponding non-oxidized precursors. For each
232 lipid, the observed *m/z* was first multiplied by the nominal-to-exact hydrogen mass ratio
233 (1.000000/1.007825032) to calculate the Kendrick mass, which was subsequently rounded to
234 the nearest integer to obtain the nominal Kendrick mass. H-KMD was then calculated as the
235 difference between the Kendrick mass and the nominal Kendrick mass. The resulting H-KMD
236 values of the OxPLs were plotted against their retention times. OxPLs were annotated as
237 potential ISF products if they met any of the following criteria: (1) they had the same (within a

238 ±0.05 min tolerance) or a later retention time than the corresponding non-oxidized lipids; (2)
239 they had the same retention time (within a ±0.05 min tolerance), as lipids with the same
240 backbone but more labile oxidative modifications; or (3) their retention times were significantly
241 later (>2 min) than the corresponding isomers with the same modifications.

242

243 **Quantification of Non-oxidized and Oxidized Lipids in Fenton Reaction and H₂O₂-only** 244 **Oxidized Lipid References**

245 We observed that peak areas of deuterated internal standards included in the Fenton- and
246 H₂O₂-only samples showed large variation between replicates, likely due to degradation in the
247 presence of H₂O₂ and/or Fe²⁺. Therefore, we used relative quantification by normalizing each
248 lipid to the total peak area of all detected lipids in analyzing oxidized and non-oxidized lipids
249 from these samples. Peak integration of all OxPLs was manually inspected. When a peak was
250 only partially integrated by MS-DIAL, the peak start and end points were manually adjusted to
251 cover the entire chromatographic peak, using samples with clearly defined peak boundaries as
252 references.

253

254 For cardiolipin (CL), PE, LPE, PG, PI, PS, FA, EtherPE-O, oxidized PE (OxPE), oxidized PG
255 (OxPG), and oxidized PS (OxPS), quantification was done using [M-H]⁻ adduct. For PC, LPC,
256 EtherPC-O, EtherPE-P, EtherLPC-O, and EtherLPE-O, quantification was done using [M+H]⁺
257 adduct. For DG and TG, quantification was done using [M+NH₄]⁺ adduct. For OxPC with
258 oxidative modifications other than carboxy (<COOH>) modification and oxidized EtherPC
259 (OxEtherPC), quantification was done using [M+HCOO]⁻ adducts rather than [M+H]⁺ adducts
260 (as used in their non-oxidized counterparts) because the detected lipid intensity is higher in
261 negative mode owing to oxidation modifications.⁴² For oxidized PC (OxPC) with carboxy
262 (<COOH>) modifications, quantification was done using [M-H]⁻ adducts, because the carboxyl
263 group provides an acidic site that facilitates deprotonation in negative-ion mode.^{43, 44} CV values
264 were calculated separately for each lipid at each treatment time point using normalized
265 intensities across replicates.

266

267 **Lipidomics Nomenclature**

268 Lipids were annotated according to the nomenclature of LIPID MAPS
269 (<https://www.lipidmaps.org/>). At the molecular species level, lipids were reported with their
270 constituent fatty acyl chains, with carbon number and double bond number separated by a colon
271 (e.g., PC(16:0_18:1)). At the species level, lipids were reported by the summed carbon number

272 and double bond number of all acyl chains (e.g., PC(34:1<oxo>)). For phospholipids, the fatty
273 acid side chains were separated by an underscore (“_”), indicating that the sn-position of side
274 chains were not specified. Using our mass spectrometry setup, alkyl-linked LPE and LPC
275 species (e.g. LPE(O-18:1)) exhibited the same tandem mass spectra as alkenyl-linked LPE and
276 LPC species with 1 less double bond (e.g. LPE(P-18:0), as previously reported.⁴⁵ For those
277 species, both annotations are listed and separated by “or” (e.g. LPE(O-18:1) or LPE(P-18:0)).
278 Oxidative modifications were indicated in angle brackets (“<>”), where OH, oxo, OOH, and
279 COOH denote hydroxy, keto, hydroperoxy, and carboxy modifications, respectively. Isomeric
280 species with identical chemical formula but distinct retention times were distinguished by
281 assigning alphabetical suffixes (e.g., (a), (b), (c)) in the order of increasing retention time.

282

283 **Lipidomics Reporting**

284 The lipidomic data were uploaded to Metabolomics Workbench (Study ID ST004800; DataTrack
285 ID 7357) and can be accessed at: <http://dx.doi.org/10.21228/M8NP12>

286

287 **Ferroptosis-induced Cytotoxicity Assay**

288 KP4 cells were seeded onto 96-well plates at approximately 5000 cells per well. 24 hours later,
289 cells were treated with ML210 (Sigma, SML0521) dissolved in dimethyl sulfoxide (DMSO) at
290 different concentrations as indicated and incubated for 24 hours. For rescue assay, 5 μ M
291 ferrostatin-1 (Sigma, SML0583) solution in DMSO was co-administered with different
292 concentrations of ML210 for 24 hours. Following the treatment, 10 μ L of CCK-8 solution (Cell
293 Counting Kit 8, abcam, ab228554) was added to each well and the absorbance at 460 nm was
294 measured using a Varioskan LUX multimode microplate reader (Thermo Fisher Scientific) after
295 1 hour of incubation at 37 °C.

296

297 **ML210 Treatment**

298 KP4 cells were cultured in 6-well plates. When reaching 70% confluence, cells were treated with
299 10 μ M ML210 in culture medium for 0, 20, 45, 80, 120, or 270 minutes. Following treatment,
300 medium was aspirated, and cells were washed with 2 mL ice-cold PBS twice. For untargeted
301 lipidomic analysis, one well of cells was collected for each biological replicate, with three
302 biological replicates prepared for each time point, and analyzed by LC-MS/MS following the
303 protocols described above.

304

305 **Cell Viability Assay by Flow Cytometry**

306 The viability of cells treated with 10 μ M ML210 in culture medium for 0, 20, 45, 80, 120, or 270
307 minutes was assessed using flow cytometry. Debris was first excluded based on forward and
308 side scatter characteristics, followed by removal of doublets using singlet gating. Live cells were
309 defined as DAPI-negative events, and cell viability was calculated as the percentage of DAPI-
310 negative cells within the singlet population.

311

312 **Identification of Non-oxidized and Oxidized Lipids in ML210-treated Samples**

313 Non-oxidized lipids from ML210-treated samples were identified following the same protocols as
314 described above. For OxPL identification, lipidomics data files from ML210-treated samples
315 were analyzed in MS-DIAL either alone or together with lipidomics data files from oxidized lipid
316 reference samples through four independent analyses: 1) ML210-treated samples alone; 2)
317 ML210-treated samples combined with Fenton reference samples; 3) ML210-treated samples
318 combined with H₂O₂-only reference samples; and 4) ML210-treated samples combined with
319 both Fenton and H₂O₂-only reference samples. The MS-DIAL settings and lipid validation
320 procedures were identical to those described above for OxPL identification (in "*Identification of*
321 *OxPLs in Fenton and H₂O₂-only Oxidized Lipid References*" section). CV-filtering was applied to
322 minimize false annotation of background noise. Non-oxidized lipids were retained if they had a
323 CV <20% for at least one treatment time point (including 0 min). OxPLs were retained if they
324 had a CV <20% for at least one treatment time point (excluding 0 min). The calculation of CV
325 values is described below in "*Quantification of Non-oxidized and Oxidized Lipids in ML210-*
326 *treated cells*". Identified lipids after the removal of potential ISF products (see "*Hydrogen-based*
327 *Kendrick Mass Defect (H-KMD) Analysis*" above) were used to generate the stacked bar plot for
328 comparison of number of identified OxPLs.

329

330 **Protein Quantification in ML210-treated Samples**

331 Aqueous phase was removed following Folch extraction. The remaining protein interphase was
332 washed once with 400 μ L ice-cold methanol at room temperature, then centrifuged at 3000
333 RPM for 10 min at 4 °C and dried down under nitrogen stream, before dissolving in 100 μ L of
334 5% SDS (Thermo Fisher Scientific, J63394.AK). Protein content was measured using a Pierce
335 BCA assay kit (Thermo Fisher Scientific, 23225) as previously reported following vendor's
336 instructions.⁴⁶

337

338 **Quantification of Non-oxidized and Oxidized Lipids in ML210-treated cells**

339 Non-oxidized endogenous lipids were reported in molar concentrations based on the intensity
340 ratio of the same ion adduct between endogenous lipids and the deuterated lipid standard within
341 the same lipid class with known concentration. The lipid adducts used for quantification of non-
342 oxidized lipids were the same as those used in Fenton and H₂O₂-only references. Furthermore,
343 lipid molar concentrations were then normalized to cellular protein content and expressed as
344 nmol/mg protein to account for variation in sample preparation. CV values were calculated
345 separately for each lipid at each treatment time point using normalized molar concentrations.

346
347 Peak integration of all OxPLs was manually inspected. Manual peak integration was performed
348 as described above (in "*Quantification of Non-oxidized and Oxidized Lipids in Fenton reaction*
349 *and H₂O₂-only Oxidized Lipid References*"). Molecular concentrations of oxidized lipids were
350 calculated based on the intensity ratio of the same ion adduct between oxidized lipids and the
351 deuterated lipid standard within the same lipid class with known concentration. The lipid adducts
352 used for quantification of OxPLs were the same as those used in Fenton and H₂O₂-only
353 references. CV-filtering was applied to minimize false annotation of background noise. CV of
354 normalized molar concentrations was calculated across replicates at each treatment time point
355 (excluding 0 h). OxPLs were retained if their CV was below 20% for at least one of the time
356 points.

357

358 **Principal Component Analysis (PCA) of Lipidomic Datasets**

359 PCA was performed using the `prcomp()` function in R (version 4.5.0) on log₂-transformed data
360 of normalized peak area for oxidized reference samples, and log₂-transformed data of
361 normalized lipid molar concentration for ML210-treated cells. All PCA plots were made to
362 visualize samples on principal component 1 (PC1) and principal component 2 (PC2).

363

364 **K-means Clustering on OxPLs**

365 K-means clustering was performed on Z scores of OxPL abundance using the `kmeans()`
366 function in R (version 4.5.0). Specifically, Z score, the number of standard deviations a data
367 point is away from the mean, was calculated for each OxPL across all replicates and time
368 points, and the mean Z score at each time point was used for clustering. For oxidized reference
369 samples, total abundances of normalized peak area of commonly detected 57 OxPLs from
370 Fenton and H₂O₂-only references were used as input. K-means clustering was then performed
371 on the Z score-transformed data with the number of clusters set to 9. For ML210-treated cells,
372 normalized lipid molar concentrations of 22 identified OxPLs were used as input. K-means

373 clustering was then performed on the Z score-transformed data with the number of clusters set
374 to 3.

375

376 **Heatmap Visualization**

377 Heatmap visualization was performed using ComplexHeatmap package (version 2.24.1). For
378 Fenton and H₂O₂ references, the intensity of each OxPL was normalized to the total OxPL
379 intensity within the same sample to calculate its relative abundance. In each replicate, relative
380 abundance of OxPLs was averaged across treatment time points (excluding 0 h). Missing
381 values were imputed with 5% of the minimum non-missing value across all replicates to enable
382 row-wise Z score transformation. The resulting Z scores were used for heatmap visualization,
383 with original missing values indicated as not detected rather than displayed based on imputed
384 values. OxPLs were grouped according to oxidative modification type, and columns were
385 grouped by reference type.

386

387 For ML210-treated cells, molar concentration of each OxPL was transformed into Z score
388 across samples for visualization. Rows were grouped based on the K-means clusters
389 determined above. Columns were arranged based on ML210 treatment time points in increasing
390 order.

391

392 **Lipid Peroxidation Assay**

393 For BODIPY C11 staining, cells were incubated with medium containing 5 µM BODIPY 581/591
394 C11 (Thermo Fisher Scientific, D3861) in DMSO for 30 min at 37 °C. Cells were then trypsinized
395 by 0.25% trypsin-EDTA (Gibco, 25200-056), washed with 2 mL of Hank's balanced salt solution
396 (Gibco, 14175-095), and analyzed using a BD Symphony flow cytometer. At least 100,000
397 events were analyzed for each sample. Reduced and oxidized BODIPY 581/591 C11 signal was
398 measured in PE-Texas Red channel (610/20 nm) and FITC channel (515/25 nm), respectively.
399 Peroxidation-positive cells were defined as the proportion of FITC-positive population of total
400 live cells based on gating determined from untreated controls.

401

402 **Correlation between OxPL Abundance by LC-MS/MS and Peroxidative Burden by BODIPY** 403 **C11 Peroxidation Assay in ML210-treated Cells**

404 Pearson correlation analysis was performed between percentage of peroxidation-positive cells
405 and total OxPL abundance. Specifically, total OxPL concentration in each sample of individual
406 time point was first calculated by aggregating normalized molar concentrations of all identified

407 OxPLs. Next, Z scores of total OxPL abundance were then calculated and averaged within each
408 time point. Similarly, Z scores of peroxidation-positive cells treated with ML210 were calculated
409 and averaged within each time point. Subsequently, the mean Z scores of peroxidation-positive
410 cells were compared to the mean Z scores of total OxPL abundance by Pearson correlation.

411
412 Pearson correlation was performed between percentage of peroxidation-positive cells and each
413 of the 3 OxPL clusters identified by K-means clustering. For each cluster, total concentration of
414 OxPLs was first calculated by aggregating normalized molar concentrations of all identified
415 OxPLs. Next, Z scores of total OxPL abundance were then calculated and averaged within each
416 time point. Lastly, the mean Z scores of peroxidation-positive cells across ML210 treatment
417 times (described above) were compared to the mean Z scores of total OxPL abundance of each
418 OxPL cluster by Pearson correlation.

419

420 **Statistical Analyses**

421 For comparisons between two groups, *P* values were calculated using Welch's *t*-test following
422 confirmation of data normality. For comparisons involving three or more groups, *P* values were
423 calculated using Welch's *t*-test following confirmation of data normality and adjusted for multiple
424 comparisons using the Benjamini–Hochberg method.

425

426 **RESULTS AND DISCUSSION**

427 **Reference-assisted Identification of Sample-specific Oxidized Phospholipid (RISOP)**

428 In biological samples, non-oxidized phospholipids account for approximately 40–70% of the total
429 mammalian lipidome.^{47, 48} In contrast, oxidized phospholipids (OxPLs) are very low in
430 abundance, generally estimated to be less than 5% of their non-oxidized counterparts.⁴⁹⁻⁵¹

431 Reliable detection and accurate annotation have long been a challenge in the field, as these
432 low-abundance lipids often fail to generate sufficiently informative tandem mass spectra
433 (MS/MS) that are necessary for structural annotation (**Figure 1A**). To overcome this challenge,
434 we reasoned that creating a pool of oxidized phospholipid references would yield high-quality
435 spectral data. This reference pool was designed to enrich OxPL species present in greater
436 number and abundance, which is critical for the identification of otherwise difficult-to-detect
437 OxPLs from biological samples. We generated OxPL references by subjecting a subset of
438 biological samples to two chemical reactions – Fenton reaction, which is initiated by Fe²⁺ and
439 H₂O₂,^{37, 52} as well as treatment with H₂O₂ alone. We used these two reactions because it has
440 been reported that Fenton reaction induces strong and non-selective oxidation by producing

441 highly reactive hydroxyl radicals via ferrous ion-mediated reactions,⁵³⁻⁵⁵ whereas oxidation by
442 H₂O₂ alone (H₂O₂-only hereafter) proceeds under metal-limited conditions and is therefore
443 comparatively milder, likely relying on endogenous metal ions present in biological samples.⁵⁶⁻⁵⁸
444 Therefore, chemically-enriched OxPL reference pools from these two reactions will likely expand
445 the reference repertoire and enhance our ability to identify and annotate OxPLs.
446 We refer to this method as Reference-Assisted Identification of Sample-specific Oxidized
447 Phospholipids (RISOP). RISOP integrates four steps (**Figure 1B**), combining empirical
448 reference spectra with an *in silico*-defined search space to enable annotation of low-abundance
449 OxPLs that would otherwise lack interpretable MS/MS evidence. **1) Untargeted lipidomic**
450 **profiling of the biological sample.** Lipids are extracted and profiled by LC-MS/MS; non-
451 oxidized lipids are annotated against established libraries and used to define the sample's
452 native phospholipid composition. **2) Generation of chemically enriched OxPL reference**
453 **pools.** In parallel, a subset of the biological sample is subjected to two oxidation reactions,
454 Fenton (Fe²⁺/ H₂O₂) and H₂O₂-only. Each oxidation reaction is sampled at multiple time points to
455 capture OxPLs across a range of oxidation depths and abundances.^{37, 59} Reference samples are
456 profiled by LC-MS/MS on the same platform as the biological sample, providing empirical
457 MS/MS spectra and retention-time anchors for OxPL features at concentrations sufficient for
458 confident structural annotation. **3) Construction of a sample-specific *in silico* OxPL spectral**
459 **library.** Non-oxidized phospholipid annotations from Step 1 are passed to LPPtiger 2,^{43, 60} which
460 performs *in silico* oxidation to generate predicted OxPL structures and their theoretical MS/MS
461 spectra. The library is therefore constrained to plausible OxPLs derived from the phospholipid
462 species actually present in the sample, focusing the annotation search on the most biologically
463 relevant species and minimizing false annotation.^{33, 43} **4) Reference-assisted OxPL**
464 **annotation.** OxPLs in the biological sample are identified when they match (i) the retention time
465 and *m/z* of an OxPL feature in the experimental reference pool, and (ii) the predicted MS/MS
466 spectrum from the sample-specific *in silico* library. Critically, by including supporting MS/MS
467 spectra from the reference pool when the species is below the MS/MS-quality threshold in the
468 biological sample itself, RISOP recovers annotations for OxPLs that conventional untargeted
469 lipidomics would miss.

470

471 **Oxidized Phospholipids Identification in Fenton and H₂O₂-only References**

472 We used Fenton reaction and H₂O₂-only treatment to generate oxidized phospholipid (OxPL)
473 references. While most previous studies have used reaction times of 12 to 24 hours,^{37, 59} we
474 included multiple time points for both reaction types to capture a broader range of oxidation

475 products in different intensities. We then performed untargeted lipidomic analysis by LC-MS/MS
476 to obtain the global lipidome of oxidized and non-oxidized lipids in all reference samples (**Figure**
477 **2A, Table S3, and Table S4**). Our lipidomics platform demonstrates analytical precision and
478 system stability, which ensures accurate retention time and *m/z* matching required for RISOP
479 (**Figure S1**). We identified a combined number of 79 OxPLs from Fenton reaction and H₂O₂-only
480 references by using the sample-specific OxPL spectral library generated in these references.
481 Importantly, because many OxPLs are of low abundance, we excluded species that were not
482 reproducibly detected across replicates to minimize false annotation of background noise
483 (coefficient of variation < 20%, see Methods), leaving 74 OxPLs for further analysis. In addition,
484 oxidized lipids are generally labile and can undergo in-source fragmentation (ISF) – an
485 artifactual fragmentation introduced during data acquisition that does not represent the true
486 biological sample.^{60, 61} These undesired ISF products often exhibit identical or longer retention
487 times compared to their non-oxidized counterparts, contributing another source of false
488 annotation.⁶⁰⁻⁶² To minimize misannotation of OxPLs from ISF products, identified OxPLs were
489 visualized using retention time versus hydrogen-based Kendrick mass defect (H-KMD) plots.⁶⁰
490 This approach allowed us to identify and exclude 7 potential ISF products (based on retention
491 time, see Methods) from the 74 OxPLs in oxidized lipid references (**Figure S2**).

492
493 To compare OxPLs generated by each oxidation chemistry, Fenton and H₂O₂-only references
494 were first analyzed independently. Of the 67 OxPLs identified across the two reference types,
495 33 were unique to Fenton, 17 were unique to H₂O₂-only, and only 17 were annotated in both
496 (**Figure 2B**). Two distinct sources contribute to this limited overlap. First, the two chemistries
497 generate partially non-overlapping product repertoires. For example, PC(16:0_18:3<2OH>) was
498 identified only in Fenton references (**Figure 2C**), consistent with the more aggressive radical
499 chemistry of the Fenton reaction. Second, OxPLs present at low abundance in one reaction type
500 may fail to yield interpretable MS/MS spectra and remain unannotated even when the OxPL
501 feature itself is detected. For instance, PS(18:0_9:0<oxo>) was detected as an OxPL feature in
502 both reference types but lacked MS/MS spectra in the Fenton-derived references, where its
503 abundance was lower (**Figure 2C**). The latter source of missed annotations is analytical rather
504 than chemical and motivates the integrated reference-assisted analysis of RISOP.

505
506 **Reference-assisted Combined Analysis on OxPL References Expands Identification**
507 **Coverage and Dynamic Range of OxPLs**

508 To test whether reference-assisted analysis could enhance OxPL identification beyond what
509 either reference type yields alone, we analyzed all reference samples from Fenton and H₂O₂-
510 only treatment together (**Figure 3A**). In this integrated analysis, an MS/MS spectrum acquired in
511 one reaction type is permitted to support annotation of a feature at matching retention time and
512 *m/z* in the other reaction type, provided the spectrum also matches a predicted spectrum from
513 the sample-specific *in silico* OxPL library. This addresses a key limitation observed in the
514 separate analyses (**Figure 2B**): many OxPL features are present in both reaction types but fall
515 below the abundance threshold required to generate interpretable MS/MS spectra in one of
516 them, and are therefore left unannotated when each reference is analyzed in isolation.
517 Consistent with this rationale, integrated analysis yielded 57 OxPLs annotated in both reference
518 types, representing a marked increase from the 17 overlapping species recovered by separate
519 analysis (**Figure 2B**) without changing the union of 67 identified OxPLs (**Figure 3A**). The
520 expanded overlap therefore reflects analytical recovery of true co-occurrence rather than a
521 change in the underlying OxPL repertoire, demonstrating that MS/MS sharing between reaction
522 types within RISOP rescues annotation of low-abundance OxPLs that would otherwise be
523 missed. Beyond identification count, the two reaction types differed in the types of oxidative
524 modification they enriched. Among the 67 identified OxPLs, species carrying hydroperoxy
525 modifications (<OOH>), products of the early oxidation cascade,^{5, 6} were relatively more
526 abundant in Fenton references. Fenton references also contained a considerably larger fraction
527 of OxPLs bearing three oxidative modifications per molecule (**Figure 3B**), consistent with the
528 high reactivity of hydroxyl radicals generated in this system and indicating that Fenton chemistry
529 promotes more extensive per-molecule oxidation. Together, these results show that RISOP's
530 reference-assisted approach substantially expands OxPL annotation while preserving
531 informative differences in modification profile between the two oxidation chemistries.

532
533 Enhanced OxPL identification enables global OxPL analyses that are otherwise restricted to a
534 limited number of OxPLs. Principal Component Analysis (PCA) on OxPLs revealed that Fenton
535 reference samples with varying reaction time formed distinct clusters that were clearly
536 separated from those of the H₂O₂-only references (**Figure 3C**). In addition, oxidized reference
537 samples were well separated by reaction time along principal component 1 and 2, suggesting
538 progressive temporal changes in OxPL composition under both Fenton and H₂O₂-only oxidation
539 conditions when all samples were plotted together (**Figure 3C**), or separately by reaction type
540 (**Figure 3D, 3E**). PCA on over 710 non-oxidized lipids largely recapitulated clustering by

541 oxidation reaction and reaction time (**Figure S3A-S3C**). Thus, global OxPL analysis reveals
542 time-dependent, progressive changes in OxPL profiles under both oxidation conditions.

543

544 To further examine changes of OxPL at individual lipid level, we performed K-means clustering
545 on identified OxPLs to uncover groups of OxPLs that exhibit similar temporal trajectory.^{63, 64}
546 Though a few clusters capture lipids with similar time-dependent changes in intensity from both
547 types of references, the majority of identified clusters reveal distinct patterns that are
548 predominantly found in either Fenton or H₂O₂-only references (**Figure 3F**). Specifically, clusters
549 1, 8, and 9 were mostly associated with the Fenton reaction, whereas clusters 2 and 6 were
550 enriched under H₂O₂-only oxidation, indicating divergent OxPL formation dynamics between
551 these two types of oxidation reactions. Thus, these results indicated that oxidation reactions of
552 Fenton and H₂O₂-only treatments produce OxPLs with different temporal patterns (**Figure 3F**).
553 Together, a reference pool created with 2 oxidation reactions and 5 time points expands the
554 coverage and dynamic range of OxPLs that will aid in enhanced identification of OxPLs in
555 biological samples.

556

557 **Applying RISOP in Studying Ferroptosis-associated Lipid Peroxidation**

558 To demonstrate the application of RISOP to studying lipid peroxidation, we applied this method
559 to investigate ferroptosis, an iron-dependent cell death characterized by hallmark accumulation
560 of lipid peroxidation.^{65, 66} We used KP4 cells, a human pancreatic ductal cell carcinoma cell line
561 with known susceptibility to ferroptosis as our model.⁶⁷ We verified that the viability of KP4 cells
562 is sensitive to ferroptosis inducer ML210 in a dose-dependent manner, and can be rescued by
563 co-treatment with ferrostatin-1 (Fer-1), a selective inhibitor of ferroptosis (**Figure S4A**).⁶⁸

564

565 We harvested KP4 cells treated with ML210 at 6 different time points for lipidomic analysis
566 (**Figure 4A, Table S5**). The dose and time points were chosen at which cells had not yet
567 undergone ferroptosis (**Figure S4B**), but may have already accumulated different levels of lipid
568 peroxidation. We first compared the number of OxPLs identified in ML210-treated samples
569 alone in the absence of any references, or from combined analyses using one or both types of
570 OxPL references through RISOP (**Figure 4B**). As expected, in the absence of Fenton or H₂O₂-
571 only references, only 9 OxPLs were identified in ML210-treated cells. Incorporation of reference
572 samples obtained from either Fenton or H₂O₂-only treatment substantially increased
573 identification of OxPLs. Notably, the combined use of all references more than doubled the
574 number of OxPLs from 9 to 22, demonstrating the power of RISOP in enhancing the

575 identification of oxidized lipid species in biological samples (**Figure 4B**). The molar
576 concentrations of OxPLs quantified in our samples were in good agreement with previously
577 reported endogenous levels of oxidized phospholipids in mammalian cells and tissues.
578 Specifically, our total OxPC (0.19-0.37 nmol/mg protein) and total OxPE (0.09-0.15 nmol/mg
579 protein) are comparable to the total OxPC and OxPE quantified in mouse peritoneal
580 macrophages by LC-MS/MS (after protein-per-cell conversion based on typical mammalian
581 cells),³³ which fall within the same sub-nmol/mg protein order of magnitude. Expressed as a
582 fraction of the parent non-oxidized phospholipid pool, our total OxPC/total PC (0.09-0.13 mol%)
583 and total OxPE/total PE (0.27-0.34 mol%) ratios fall within the <1–2 mol% range typically
584 associated with endogenous, non-pathological membrane oxidation.^{50, 69} Collectively, these
585 comparisons indicate that OxPLs detected in our study are consistent with previously reported
586 endogenous oxidized phospholipid content in mammalian cells. To assess changes in the global
587 lipidome, we performed PCA on all OxPLs identified in ML210-treated cells (**Figure 4C**). Our
588 results revealed some separation in cells with longer ML210 treatment, indicating that ML210
589 induces changes in OxPL composition. Notably, analysis of non-oxidized lipids exhibited a
590 similar clustering with increasing treatment time, suggesting that an elevated lipid peroxidation
591 burden is accompanied by remodeling of the native, non-oxidized lipid environment as well
592 (**Figure 4D**).

593
594 We next performed K-means clustering to further characterize the temporal changes of OxPL.
595 We observed that OxPLs could be classified into three distinct clusters based on their temporal
596 trajectories, each exhibiting a distinct pattern over time. Specifically, Cluster 1 remained
597 relatively stable at early time points (0 – 45 min) and then decreased at later time points (≥ 80
598 min). Cluster 2 increased over time, peaked at 120 min, and then slightly declined. Cluster 3
599 showed an initial decrease followed by a marked increase, reaching the highest level at 270 min
600 (**Figure 4E, 4F**). These results suggest that lipid peroxidation is a dynamic process, wherein
601 elevated cellular oxidative burden leads to distinct responses in subgroups of OxPLs. Together,
602 these results demonstrate that reference-assisted analysis using RISOP with oxidized lipid
603 references markedly improves identification of OxPLs in biological samples undergoing
604 increased oxidative stress.

605 606 **Lipid Peroxidation Assessment by BODIPY C11 and OxPL Profiling**

607 Currently, one of the most widely used methods for assessing lipid peroxidation in live cells is
608 the BODIPY C11 probe, which detects lipid radicals, a peroxidation intermediate, through

609 oxidation of its polyunsaturated C11 moiety, leading to a shift in fluorescence emission from the
610 reduced state (~590 nm) to the oxidized state (~510 nm).⁷⁰ However, it remains unclear whether
611 BODIPY C11 accurately reflects the overall burden of lipid peroxidation in living cells. To
612 address this question, we used the same treatment paradigm that we established earlier
613 (**Figure 4A**) and performed BODIPY C11 staining by flow cytometry (**Figure 5A and Figure**
614 **S5A**). The level of cellular peroxidation assessed by BODIPY C11 increased and plateaued in
615 cells treated with ML210 for 120 min, before decreasing to a similar level as a shorter treatment
616 time (**Figures 5B, 5C and Figure S5B**). To compare changes in BODIPY C11 peroxidation with
617 the level of total OxPL abundance by mass spectrometry, we performed correlation analysis
618 between the percentage of peroxidation-positive cells and the total abundance of OxPLs along
619 the course of treatment times. Interestingly, the proportion of peroxidation-positive cells did not
620 correlate with total OxPL abundance in cells (**Figure S6**), suggesting that the BODIPY C11
621 signal may not reflect changes in overall OxPL abundance. However, when the percentage of
622 peroxidation-positive cells was compared to each distinct temporal OxPL cluster that we
623 identified (**Figure 4E**), a significant positive correlation was observed specifically with Cluster 2
624 (**Figure 5D**, $P = 0.004$, Pearson correlation followed by Benjamini–Hochberg correction).
625 Cluster 2 contains a larger number of OxPLs with hydroperoxy modifications (<OOH>) than the
626 other 2 clusters (**Figure 4F**). Given that lipids with hydroperoxy modifications (<OOH>) are the
627 direct product of the same radical chemistry that BODIPY C11 reacts to,⁷⁰ it is therefore
628 plausible that the abundance of OxPLs in Cluster 2 correlates with the readout of BODIPY C11.
629 These results suggest that BODIPY C11 may only capture the oxidative burden of a subset of
630 OxPLs in live cells. The lack of a global correlation between BODIPY C11 and total OxPL
631 abundances likely arises from their fundamentally different readouts. Specifically, BODIPY C11
632 reports ongoing radical-mediated lipid peroxidation,⁷¹ whereas lipidomics-based OxPL analysis
633 captures a broad spectrum of oxidized lipid products, including both early- and late-stage
634 oxidation products. These results highlight the need for comprehensive identification of OxPLs
635 in understanding their contribution to key cellular processes.

636

637 **CONCLUSIONS**

638 In this study, we developed RISOP, a reference-assisted approach for enhanced identification of
639 oxidized phospholipids (OxPLs) in an untargeted lipidomics workflow by LC-MS/MS. The core
640 advance of RISOP is to generate chemically enriched OxPL reference pools from the same
641 biological matrix using Fenton and H₂O₂-only oxidation, providing high-quality MS/MS spectra
642 and retention-time anchors for OxPLs that are otherwise too scarce to be annotated directly. By

643 sharing MS/MS evidence across the two reaction types and matching against a sample-specific
644 *in silico* spectral library, RISOP recovers identifications for low-abundance OxPLs while
645 constraining the search to biologically plausible species. This strategy more than doubled the
646 number of OxPLs identified in ferroptosis-induced KP4 cells, without requiring modifications to
647 instrumentation or data acquisition. Beyond method development, we found that the widely used
648 BODIPY C11 lipid peroxidation probe captures oxidative burden in only a subset of OxPLs in
649 live cells – underscoring the need for comprehensive, untargeted characterization of the OxPL
650 landscape in biological processes. RISOP is generalizable and can be applied to studies of
651 different cell and tissue types beyond cultured cell systems. Our method can be expanded to
652 investigate other classes of oxidized complex lipids, including oxidized glycerol lipids, offering a
653 broadly applicable platform for lipidomics studies. The improved identification capability
654 established here lays the groundwork for future mechanistic investigations into the functional
655 roles of oxidized complex lipids in physiology and disease.

656

657 **AUTHOR INFORMATION**

658 **Corresponding Author**

659 **Xiaoai Zhao** – Department of Comparative Medicine, Yale School of Medicine, New Haven,
660 Connecticut 06510, USA; Yale Center for Molecular and Systems Metabolism, Yale School of
661 Medicine, New Haven, Connecticut 06510, USA; Wu Tsai Institute, Yale School of Medicine,
662 New Haven, Connecticut 06510, USA; orcid.org/0000-0001-6602-0838; Email:
663 xiaoai.zhao@yale.edu

664

665 **Authors**

666 **Zixing Chen** – Department of Comparative Medicine, Yale School of Medicine, New Haven,
667 Connecticut 06510, USA; orcid.org/0000-0002-9313-5312

668 **Andrew Erickson** – Department of Comparative Medicine, Yale School of Medicine, New
669 Haven, Connecticut 06510, USA; orcid.org/0009-0009-3561-767X

670 **Natalie Ito** – Department of Comparative Medicine, Yale School of Medicine, New Haven,
671 Connecticut 06510, USA

672

673 **Author Contributions**

674 Z.C. designed the project under the guidance of X.Z.. Z.C. performed all experiments and data
675 analyses. A.E. conducted independent code checking and accuracy checks. A.E. and N.I.

676 provided feedback on graphic design and the written manuscript. Z.C. wrote the manuscript with
677 X.Z..

678

679 **Acknowledgements**

680 This work was supported by a translational geroscience pilot award from the Yale Claude D.
681 Pepper Older Americans Independence Center (X.Z.) and McCance Fellowship (X.Z.). We
682 thank Dr. Mandar Muzumdar at Yale School of Medicine for generously providing the KP4 cell
683 line used in this study. We thank Yale Flow Cytometry for their assistance with flow cytometry
684 analysis. Schematic diagrams were created with BioRender.com.

685

686 **Data availability**

687 The lipidomic data were uploaded to Metabolomics Workbench (Study ID ST004800; DataTrack
688 ID 7357) and can be accessed at: <http://dx.doi.org/10.21228/M8NP12>

689

690 **Code availability**

691 The R scripts generated for this study can be accessed at: [https://github.com/ZhaoLab-](https://github.com/ZhaoLab-Yale/RISOP_R_code)
692 [Yale/RISOP_R_code](https://github.com/ZhaoLab-Yale/RISOP_R_code)

693

694

695 **References**

696 (1) Durand, E.; Laguerre, M.; Bourlieu-Lacanal, C.; Lecomte, J.; Villeneuve, P. Navigating the
697 complexity of lipid oxidation and antioxidation: A review of evaluation methods and emerging
698 approaches. *Prog. Lipid Res.* **2025**, *97*, 101317.

699 (2) Wang, M.; Yang, B.; Shao, P.; Jie, F.; Yang, X.; Lu, B. Sterols and Sterol Oxidation Products:
700 Effect of Dietary Intake on Tissue Distribution in ApoE-Deficient Mice. *J. Agric. Food Chem.* **2021**,
701 *69* (40), 11867–11877.

702 (3) Brown, A. J.; Dean, R. T.; Jessup, W. Free and esterified oxysterol: formation during copper-
703 oxidation of low density lipoprotein and uptake by macrophages. *J. Lipid Res.* **1996**, *37* (2), 320–
704 335.

705 (4) Reis, A. Oxidative Phospholipidomics in health and disease: Achievements, challenges and
706 hopes. *Free Radical Biology and Medicine* **2017**, *111*, 25–37.

707 (5) Yin, H.; Xu, L.; Porter, N. A. Free radical lipid peroxidation: mechanisms and analysis. *Chem.*
708 *Rev.* **2011**, *111* (10), 5944–5972.

709 (6) O'Donnell, V. B.; Aldrovandi, M.; Murphy, R. C.; Krönke, G. Enzymatically oxidized
710 phospholipids assume center stage as essential regulators of innate immunity and cell death.
711 *Science Signaling* **2019**, *12* (574), eaau2293.

712 (7) Naguib, Y. M. A fluorometric method for measurement of peroxy radical scavenging activities
713 of lipophilic antioxidants. *Anal. Biochem.* **1998**, *265* (2), 290–298.

714 (8) Yamanaka, K.; Saito, Y.; Sakiyama, J.; Ohuchi, Y.; Oseto, F.; Noguchi, N. A novel fluorescent
715 probe with high sensitivity and selective detection of lipid hydroperoxides in cells. *RSC advances*
716 **2012**, *2* (20), 7894–7900.

717 (9) Spickett, C. M. The lipid peroxidation product 4-hydroxy-2-nonenal: advances in chemistry and
718 analysis. *Redox biology* **2013**, *1* (1), 145–152.

719 (10) Chen, J.; Zeng, L.; Xia, T.; Li, S.; Yan, T.; Wu, S.; Qiu, G.; Liu, Z. Toward a biomarker of
720 oxidative stress: a fluorescent probe for exogenous and endogenous malondialdehyde in living
721 cells. *Anal. Chem.* **2015**, *87* (16), 8052–8056.

722 (11) Binder, C. J.; Papac-Milicevic, N.; Witztum, J. L. Innate sensing of oxidation-specific epitopes
723 in health and disease. *Nature Reviews Immunology* **2016**, *16* (8), 485–497.

724 (12) Que, X.; Hung, M.-Y.; Yeang, C.; Gonen, A.; Prohaska, T. A.; Sun, X.; Diehl, C.; Määttä, A.;
725 Gaddis, D. E.; Bowden, K. Oxidized phospholipids are proinflammatory and proatherogenic in
726 hypercholesterolaemic mice. *Nature* **2018**, *558* (7709), 301–306.

727 (13) Haberzettl, P.; Hill, B. G. Oxidized lipids activate autophagy in a JNK-dependent manner by
728 stimulating the endoplasmic reticulum stress response. *Redox biology* **2013**, *1* (1), 56–64.

729 (14) Lin, Z.; Long, F.; Kang, R.; Klionsky, D. J.; Yang, M.; Tang, D. The lipid basis of cell death and
730 autophagy. *Autophagy* **2024**, *20* (3), 469–488.

731 (15) Tyurina, Y. Y.; Kapralov, A. A.; Tyurin, V. A.; Shurin, G.; Amoscato, A. A.; Rajasundaram, D.;
732 Tian, H.; Bunimovich, Y. L.; Nefedova, Y.; Herrick, W. G. Redox phospholipidomics discovers pro-
733 ferroptotic death signals in A375 melanoma cells in vitro and in vivo. *Redox Biology* **2023**, *61*,
734 102650.

735 (16) Lei, G.; Zhuang, L.; Gan, B. Targeting ferroptosis as a vulnerability in cancer. *Nature Reviews*
736 *Cancer* **2022**, *22* (7), 381–396.

737 (17) Lee, S.; Birukov, K. G.; Romanoski, C. E.; Springstead, J. R.; Luscis, A. J.; Berliner, J. A. Role
738 of phospholipid oxidation products in atherosclerosis. *Circulation research* **2012**, *111* (6), 778–
739 799.

740 (18) Tsimikas, S.; Witztum, J. L. Oxidized phospholipids in cardiovascular disease. *Nature*
741 *Reviews Cardiology* **2024**, *21* (3), 170–191.

742 (19) Boffa, M. B.; Koschinsky, M. L. Oxidized phospholipids as a unifying theory for lipoprotein (a)
743 and cardiovascular disease. *Nature Reviews Cardiology* **2019**, *16* (5), 305–318.

744 (20) Dong, Y.; Yong, V. W. Oxidized phospholipids as novel mediators of neurodegeneration.
745 *Trends Neurosci.* **2022**, *45* (6), 419–429.

746 (21) Dong, Y.; D’Mello, C.; Pinsky, W.; Lozinski, B. M.; Kaushik, D. K.; Ghorbani, S.; Moezzi, D.;
747 Brown, D.; Melo, F. C.; Zandee, S. Oxidized phosphatidylcholines found in multiple sclerosis
748 lesions mediate neurodegeneration and are neutralized by microglia. *Nat. Neurosci.* **2021**, *24* (4),
749 489–503.

750 (22) Liu, J.; Li, W.; Chen, R.; McIntyre, T. M. Circulating biologically active oxidized phospholipids
751 show on-going and increased oxidative stress in older male mice. *Redox Biology* **2013**, *1* (1),
752 110–114.

753 (23) Palmieri, M.; Almeida, M.; Nookaew, I.; Gomez-Acevedo, H.; Joseph, T. E.; Que, X.; Tsimikas,
754 S.; Sun, X.; Manolagas, S. C.; Witztum, J. L.; et al. Neutralization of oxidized phospholipids
755 attenuates age-associated bone loss in mice. *Aging Cell* **2021**, *20* (8), e13442.

756 (24) Spickett, C. M.; Pitt, A. R. Oxidative lipidomics coming of age: advances in analysis of
757 oxidized phospholipids in physiology and pathology. *Antioxid Redox Signal* **2015**, *22* (18), 1646–
758 1666.

759 (25) Strassburg, K.; Huijbrechts, A. M.; Kortekaas, K. A.; Lindeman, J. H.; Pedersen, T. L.; Dane,
760 A.; Berger, R.; Brenkman, A.; Hankemeier, T.; van Duynhoven, J. Quantitative profiling of oxylipins
761 through comprehensive LC-MS/MS analysis: application in cardiac surgery. *Anal. Bioanal. Chem.*
762 **2012**, *404* (5), 1413–1426.

763 (26) Welch, B. M.; Bommarito, P. A.; Cantonwine, D. E.; Milne, G. L.; Motsinger-Reif, A.; Edin, M.
764 L.; Zeldin, D. C.; Meeker, J. D.; McElrath, T. F.; Ferguson, K. K. Predictors of upstream
765 inflammation and oxidative stress pathways during early pregnancy. *Free Radic. Biol. Med.* **2024**,
766 *213*, 222–232.

767 (27) Damiani, T.; Bonciarelli, S.; Thallinger, G. G.; Koehler, N.; Krettl, C. A.; Salihoğlu, A. K.; Korf,
768 A.; Pauling, J. K.; Pluskal, T.; Ni, Z.; et al. Software and Computational Tools for LC-MS-Based
769 Epilipidomics: Challenges and Solutions. *Anal. Chem.* **2023**, *95* (1), 287–303.

770 (28) Spickett, C. M. Formation of oxidatively modified lipids as the basis for a cellular epilipidome.
771 *Frontiers in endocrinology* **2020**, *11*, 602771.

772 (29) Simões, C.; Silva, A. C.; Domingues, P.; Laranjeira, P.; Paiva, A.; Domingues, M. R. M.
773 Phosphatidylethanolamines glycation, oxidation, and glycooxidation: effects on monocyte and
774 dendritic cell stimulation. *Cell Biochem. Biophys.* **2013**, *66* (3), 477–487.

775 (30) Nayeem, M. A. Role of oxylipins in cardiovascular diseases. *Acta Pharmacol. Sin.* **2018**, *39*
776 (7), 1142–1154.

777 (31) Barker-Tejeda, T. C.; Villaseñor, A.; Gonzalez-Riano, C.; López-López, Á.; Gradillas, A.;
778 Barbas, C. In vitro generation of oxidized standards for lipidomics. Application to major membrane
779 lipid components. *J Chromatogr A* **2021**, *1651*, 462254.

780 (32) Morel, Y.; Jones, J. W. Utilization of LC–MS/MS and drift tube ion mobility for characterizing
781 intact oxidized arachidonate-containing glycerophosphatidylethanolamine. *Journal of the*
782 *American Society for Mass Spectrometry* **2023**, *34* (8), 1609–1620.

783 (33) Aoyagi, R.; Ikeda, K.; Isobe, Y.; Arita, M. Comprehensive analyses of oxidized phospholipids
784 using a measured MS/MS spectra library. *J. Lipid Res.* **2017**, *58* (11), 2229–2237.

785 (34) Garza, S.; James, G.; Park, H. G.; Baker, P. R.; Brenna, J. T. Analysis of intact in vivo
786 peroxidized phospholipids from bovine retina via LC-MS/MS and GC-MS/MS using autoxidized
787 retina reference standards. *Anal. Chem.* **2024**, *96* (38), 15406–15413.

788 (35) Zhou, Z.; Huang, X.; Zhang, Y.-Y.; Cui, S.; Wang, Y.; Dong, M.; Zhou, D.; Zhu, B.; Qin, L. In
789 silico-predicted dynamic oxlipidomics MS/MS library: High-throughput discovery and
790 characterization of unknown oxidized lipids. *Anal. Chem.* **2024**, *96* (5), 2008–2021.

791 (36) O'Donnell, V. B. Mass spectrometry analysis of oxidized phosphatidylcholine and
792 phosphatidylethanolamine. *Biochim Biophys Acta* **2011**, *1811* (11), 818–826.

793 (37) Zschörnig, K.; Schiller, J. A simple method to generate oxidized phosphatidylcholines in
794 amounts close to one milligram. *Chem. Phys. Lipids* **2014**, *184*, 30–37.

795 (38) Folch, J.; Lees, M.; Stanley, G. S. A simple method for the isolation and purification of total
796 lipides from animal tissues. *J. Biol. Chem.* **1957**, *226* (1), 497–509.

797 (39) Köfeler, H. C.; Ahrends, R.; Baker, E. S.; Ekroos, K.; Han, X.; Hoffmann, N.; Holčapek, M.;
798 Wenk, M. R.; Liebisch, G. Recommendations for good practice in MS-based lipidomics. *J. Lipid*
799 *Res.* **2021**, *62*, 100138.

800 (40) Matsuzawa, Y.; Higashi, Y.; Takano, K.; Takahashi, M.; Yamada, Y.; Okazaki, Y.; Nakabayashi,
801 R.; Saito, K.; Tsugawa, H. Food lipidomics for 155 agricultural plant products. *J. Agric. Food Chem.*
802 **2021**, *69* (32), 8981–8990.

803 (41) Sokol, E.; Almeida, R.; Hannibal-Bach, H. K.; Kotowska, D.; Vogt, J.; Baumgart, J.;
804 Kristiansen, K.; Nitsch, R.; Knudsen, J.; Ejsing, C. S. Profiling of lipid species by normal-phase
805 liquid chromatography, nanoelectrospray ionization, and ion trap–orbitrap mass spectrometry.
806 *Anal. Biochem.* **2013**, *443* (1), 88–96.

807 (42) Carpanedo, L.; Rund, K. M.; Wende, L. M.; Kampschulte, N.; Schebb, N. H. LC-HRMS
808 analysis of phospholipids bearing oxylipins. *Anal. Chim. Acta* **2024**, *1326*, 343139.

809 (43) Ni, Z.; Angelidou, G.; Hoffmann, R.; Fedorova, M. LPPTiger software for lipidome-specific
810 prediction and identification of oxidized phospholipids from LC-MS datasets. *Sci. Rep.* **2017**, *7*
811 (1), 15138.

812 (44) Matsuoka, Y.; Takahashi, M.; Sugiura, Y.; Izumi, Y.; Nishiyama, K.; Nishida, M.; Suematsu,
813 M.; Bamba, T.; Yamada, K.-i. Structural library and visualization of endogenously oxidized
814 phosphatidylcholines using mass spectrometry-based techniques. *Nat. Commun.* **2021**, *12* (1),
815 6339.

816 (45) Ventura, G.; Bianco, M.; Calvano, C. D.; Losito, I.; Cataldi, T. R. Tandem mass spectrometry
817 in untargeted lipidomics: a case study of peripheral blood mononuclear cells. *International Journal*
818 *of Molecular Sciences* **2024**, *25* (22), 12077.

819 (46) Su, H.; Fowler, C.; Masters, C. L.; Barnham, K. J.; Reid, G. E.; Vella, L. J. Multiomics analysis
820 to evaluate the enrichment of extracellular vesicles from human plasma. *J. Lipid Res.* **2025**, *66*
821 (9).

822 (47) Kontush, A.; Lhomme, M.; Chapman, M. J. Unraveling the complexities of the HDL lipidome.
823 *J. Lipid Res.* **2013**, *54* (11), 2950–2963.

824 (48) Zhang, L.-Y.; Shi, H.-H.; Wang, C.-C.; Wang, Y.-M.; Wei, Z.-H.; Xue, C.-H.; Mao, X.-Z.; Zhang,
825 T.-T. Targeted lipidomics reveal the effects of different phospholipids on the phospholipid profiles
826 of hepatic mitochondria and endoplasmic reticulum in high-fat/high-fructose-diet-induced
827 nonalcoholic fatty liver disease mice. *J. Agric. Food Chem.* **2022**, *70* (11), 3529–3540.

828 (49) Ravandi, A.; Leibundgut, G.; Hung, M.-Y.; Patel, M.; Hutchins, P. M.; Murphy, R. C.; Prasad,
829 A.; Mahmud, E.; Miller, Y. I.; Dennis, E. A. Release and capture of bioactive oxidized phospholipids
830 and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions
831 in humans. *J. Am. Coll. Cardiol.* **2014**, *63* (19), 1961–1971.

832 (50) Bochkov, V. N.; Oskolkova, O. V.; Birukov, K. G.; Levonen, A.-L.; Binder, C. J.; Stöckl, J.
833 Generation and biological activities of oxidized phospholipids. *Antioxidants & redox signaling*
834 **2010**, *12* (8), 1009–1059.

835 (51) Wende, L. M.; Carpanedo, L.; Scholz, L.; Kampschulte, N.; West, A. L.; Calder, P. C.; Schebb,
836 N. H. Quantification of esterified oxylipins following HILIC-fractionation of lipid classes. *J. Lipid*
837 *Res.* **2025**, 100950.

838 (52) Reis, A.; Domingues, P.; Ferrer - Correia, A.; Domingues, M. Tandem mass spectrometry of
839 intact oxidation products of diacylphosphatidylcholines: evidence for the occurrence of the
840 oxidation of the phosphocholine head and differentiation of isomers. *J. Mass Spectrom.* **2004**, *39*
841 (12), 1513–1522.

842 (53) Duché, G.; Sanderson, J. M. The chemical reactivity of membrane lipids. *Chem. Rev.* **2024**,
843 124 (6), 3284–3330.

844 (54) Freinbichler, W.; Colivicchi, M. A.; Stefanini, C.; Bianchi, L.; Ballini, C.; Misini, B.; Weinberger,
845 P.; Linert, W.; Varešlija, D.; Tipton, K. F. Highly reactive oxygen species: detection, formation, and
846 possible functions. *Cell. Mol. Life Sci.* **2011**, 68 (12), 2067–2079.

847 (55) Graf, E.; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-catalyzed hydroxyl radical formation.
848 Stringent requirement for free iron coordination site. *J. Biol. Chem.* **1984**, 259 (6), 3620–3624.

849 (56) Halliwell, B.; Gutteridge, J. M. Biologically relevant metal ion-dependent hydroxyl radical
850 generation An update. *FEBS Lett.* **1992**, 307 (1), 108–112.

851 (57) Zhao, Z. Hydroxyl radical generations form the physiologically relevant Fenton-like reactions.
852 *Free Radical Biology and Medicine* **2023**, 208, 510–515.

853 (58) Ursini, F.; Maiorino, M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. *Free*
854 *Radical Biology and Medicine* **2020**, 152, 175–185.

855 (59) Santos, M.; Mauricio, T.; Domingues, R.; Domingues, P. Impact of oxidized
856 phosphatidylcholine supplementation on the lipidome of RAW264. 7 macrophages. *Arch.*
857 *Biochem. Biophys.* **2025**, 768, 110384.

858 (60) Criscuolo, A.; Nepachalovich, P.; Garcia-del Rio, D. F.; Lange, M.; Ni, Z.; Baroni, M.; Cruciani,
859 G.; Goracci, L.; Blüher, M.; Fedorova, M. Analytical and computational workflow for in-depth
860 analysis of oxidized complex lipids in blood plasma. *Nat. Commun.* **2022**, 13 (1), 6547.

861 (61) Gathungu, R. M.; Larrea, P.; Sniatynski, M. J.; Marur, V. R.; Bowden, J. A.; Koelmel, J. P.;
862 Starke-Reed, P.; Hubbard, V. S.; Kristal, B. S. Optimization of electrospray ionization source
863 parameters for lipidomics to reduce misannotation of in-source fragments as precursor ions. *Anal.*
864 *Chem.* **2018**, 90 (22), 13523–13532.

865 (62) Hu, C.; Luo, W.; Xu, J.; Han, X. Recognition and avoidance of ion source - generated artifacts
866 in lipidomics analysis. *Mass Spectrom. Rev.* **2022**, 41 (1), 15–31.

867 (63) Wu, Z.; Bagarolo, G. I.; Thoröe-Boveleth, S.; Jankowski, J. “Lipidomics”: Mass spectrometric
868 and chemometric analyses of lipids. *Adv. Drug Del. Rev.* **2020**, 159, 294–307.

869 (64) Chen, J.; Liu, C.; Ye, S.; Lu, R.; Zhu, H.; Xu, J. UPLC - MS/MS - based plasma lipidomics
870 reveal a distinctive signature in systemic lupus erythematosus patients. *MedComm* **2021**, 2 (2),
871 269-278.

872 (65) Li, J.; Cao, F.; Yin, H.-l.; Huang, Z.-j.; Lin, Z.-t.; Mao, N.; Sun, B.; Wang, G. Ferroptosis: past,
873 present and future. *Cell death & disease* **2020**, 11 (2), 88.


874 (66) Pope, L. E.; Dixon, S. J. Regulation of ferroptosis by lipid metabolism. *Trends Cell Biol.* **2023**,
875 33 (12), 1077–1087.

- 876 (67) Bhat, K. P.; Vijay, J.; Vilas, C. K.; Asundi, J.; Zou, J.; Lau, T.; Cai, X.; Ahmed, M.; Kabza, M.;
877 Weng, J. CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis.
878 *Cell reports* **2024**, 43 (6).
- 879 (68) Miotto, G.; Rossetto, M.; Di Paolo, M. L.; Orian, L.; Venerando, R.; Roveri, A.; Vučković, A.-
880 M.; Travain, V. B.; Zaccarin, M.; Zennaro, L. Insight into the mechanism of ferroptosis inhibition
881 by ferrostatin-1. *Redox biology* **2020**, 28, 101328.
- 882 (69) Reis, A.; Spickett, C. M. Chemistry of phospholipid oxidation. *Biochim Biophys Acta* **2012**,
883 1818 (10), 2374-2387.
- 884 (70) Pap, E.; Drummen, G.; Winter, V.; Kooij, T.; Rijken, P.; Wirtz, K.; Op den Kamp, J.; Hage, W.;
885 Post, J. Ratio - fluorescence microscopy of lipid oxidation in living cells using C11 -
886 BODIPY581/591. *FEBS Lett.* **1999**, 453 (3), 278-282.
- 887 (71) Drummen, G. P.; van Liebergen, L. C.; den Kamp, J. A. O.; Post, J. A. C11-BODIPY581/591,
888 an oxidation-sensitive fluorescent lipid peroxidation probe:(micro) spectroscopic characterization
889 and validation of methodology. *Free Radical Biology and Medicine* **2002**, 33 (4), 473–490.

890

Figure 1

A



B




Figure 1. Reference-assisted identification of sample-specific oxidized phospholipid (RISOP). (A) In biological samples, oxidized phospholipids (OxPLs) are often present at low abundance. Consequently, their MS spectra are often insufficiently informative, making their annotation challenging (left panel). To overcome this challenge, we experimentally generate a reference pool of oxidized lipids by 2 oxidation reactions. These references are chemically enriched for oxidized phospholipid (OxPL) species in greater number and abundance, enabling identification of low-abundance OxPLs in biological samples through retention time (RT) and mass-to-charge ratio (m/z) matching to the oxidized lipid references (right panel). (B) Workflow of RISOP. 1) Untargeted lipidomic profiling of the biological sample. Lipidomic profiles of biological samples were obtained by untargeted LC-MS/MS lipidomics. 2) Generation of chemically enriched OxPL reference pools. Oxidized lipid references were generated by subjecting a subset of the biological samples to Fenton reaction or H_2O_2 treatment alone (H_2O_2 -only) for different reaction times, followed by LC-MS/MS lipidomic analysis. 3) Construction of a sample-specific *in silico* OxPL spectral library. The endogenous non-oxidized phospholipids identified from the biological samples from step 1 were used for *in silico* oxidation. The *in silico*-generated tandem mass spectra containing diagnostic ions of each OxPL species were used to generate a sample-specific oxidized phospholipid spectral library. 4) Reference-assisted OxPL annotation. OxPL features were first detected by retention time and m/z matching between biological samples and the experimental reference pools. These features were then annotated by matching their experimental MS/MS spectra against *in silico* MS/MS spectra generated from the sample-specific spectral library. OxPLs identified in biological samples were reported following spectral validation to remove misannotated OxPLs.

Figure 2




Figure 2. Identification of oxidized phospholipids in Fenton and H₂O₂-only references. **(A)** Preparation of OxPL references. KP4 cell suspensions were subjected to Fenton reaction and H₂O₂-only treatment for 5 different reaction time points. At the end of each reaction time point, samples were harvested for lipidomic analysis by LC-MS/MS. **(B)** OxPL identification in separate Fenton and H₂O₂-only references. Venn diagram showing the number of unique and commonly identified OxPLs from Fenton and H₂O₂-only references. **(C)** Representative Fenton-unique and H₂O₂-only-unique OxPLs. Top: Extracted ion chromatograms (EIC) of two representative OxPLs PC(16:0_18:3<2OH>) (left) and PS(18:0_9:0<oxo>) (right) from Fenton references (red) and H₂O₂-only references (blue). Middle: Representative tandem mass spectra with diagnostic ions for identification. Each fragment ion is annotated with mass-to-charge ratio (*m/z*) and corresponding fragment identity or elemental composition. Fragments labeled in blue, purple, green, and red represent non-oxidized side chains, oxidized side chains, lipid class characteristic ions, and precursors or precursors with neutral loss (NL), respectively. Bottom: chemical structures of PC(16:0_18:3<2OH>) (left) and PS(18:0_9:0<oxo>) (right) with isomers not specified. Annotations follow the identical color codes as in middle panel.

Figure 3




Figure 3. Reference-assisted combined analysis on OxPL references expands identification coverage and dynamic range of OxPLs. **(A)** OxPLs identified from combined analysis of Fenton and H₂O₂-only references. Venn diagram showing the number of unique and commonly identified OxPLs from Fenton and H₂O₂-only references. **(B)** Heatmap of 67 OxPLs identified in Fenton and/or H₂O₂ references. Each row represents one OxPL, and each column represents individual replicate of the Fenton or H₂O₂-only references. Columns are grouped by reference type, and rows are grouped by distinct oxidative modifications. Z scores representing the relative abundance of each OxPL are calculated from normalized OxPL intensity and plotted. Grey squares with crosses indicate OxPLs that were not detected. **(C)** Principal component analysis (PCA) on log₂-transformed normalized intensity of 57 common OxPLs identified in Fenton (dots in shades of red and grey) and H₂O₂-only (triangles in shades of blue and grey) references from untargeted lipidomics. Each data point represents one sample at a specific time point from either Fenton or H₂O₂-only references. **(D-E)** PCA on log₂-transformed normalized intensity of 63 OxPLs identified in Fenton **(D)** and 61 OxPLs identified in H₂O₂-only **(E)** references from untargeted lipidomics. Each data point represents one sample at a specific time point from either Fenton references or H₂O₂-only references. **(F)** K-means clustering on 57 common OxPLs identified in both Fenton and H₂O₂-only references. K-means clustering was performed on normalized intensity of OxPLs in reference samples from different time points of Fenton or H₂O₂-only treatment. Number of OxPLs from Fenton or H₂O₂-only references in each cluster is indicated. Z scores of individual OxPLs (grey lines) are shown together with red and blue lines representing the mean Z score from Fenton and H₂O₂-only references, respectively. Line thickness is proportional to the number of OxPLs. Dashed line indicates a Z score of zero.

Figure 4




Figure 4. Applying RISOP in studying ferroptosis-associated lipid peroxidation. **(A)** Preparation of ML210-treated cells. KP4 cells were incubated with 10 μ M ML210 for six treatment time points. At the end of each incubation time point, samples were harvested for lipidomic analysis by LC-MS/MS. **(B)** Number of identified OxPLs in ML210-treated samples with or without RISOP. Stacked bar plot showing numbers of OxPLs identified in ML210-treated samples alone without RISOP (purple), and additional OxPLs identified using Fenton references (red), H₂O₂-only references (blue), or both Fenton and H₂O₂-only references combined (dark magenta) through RISOP. **(C)** Principal component analysis (PCA) on log₂-transformed molar concentrations of 22 OxPLs identified in ML210-treated samples. Each data point represents one sample harvested from a given time point. **(D)** PCA on log₂-transformed molar concentrations of 723 non-oxidized lipids identified in ML210-treated cells. Each data point represents one sample harvested from a given time point. **(E)** K-means clustering on 22 OxPLs identified in ML210-treated samples. K-means clustering was performed on molar concentrations of OxPLs in ML210-treated samples treated for different durations. In each cluster, number of OxPLs is indicated. Z scores of individual OxPLs (grey lines) are shown together with brown lines in different shades representing the mean Z score of each cluster. Line thickness is proportional to the number of OxPLs. Dashed line indicates a Z score of zero. **(F)** Heatmap of 22 OxPLs identified in ML210-treated samples. Each row represents one OxPL, and each column represents one biological replicate at the indicated ML210 treatment time point. Columns are grouped by treatment time and ordered from 0 to 270 min. Rows are grouped according to the K-means clusters defined in Figure 4E. Row-wise transformed Z scores of molar concentrations of OxPLs from each identified cluster are presented. Only OxPL isomers (indicated with letter suffixes in parentheses) that are identified in ML210-treated samples were included.

Figure 5





Figure 5. Lipid peroxidation assessment by BODIPY C11 and OxPL profiling. **(A)** Preparation of ML210-treated cells. KP4 cells were incubated with 10 μ M ML210 for six treatment time points. At the end of each incubation time point, samples were harvested for BODIPY C11 staining followed by flow cytometry analysis. **(B-C)** Lipid peroxidation assessed by BODIPY C11 in samples treated with ML210. **B**, Histograms of BODIPY C11 staining intensity in FITC channel (515/25 nm, representing oxidized form) by flow cytometry are shown. Area shaded in green indicates peroxidation-positive cells. **C**, Dot-and-whisker plot showing quantification of peroxidation-positive cells. Each replicate (individual dots) is shown with error bars representing mean \pm SEM ($n = 3$). Asterisk indicates significance compared to the 0 min control ($***P < 0.001$, $**P < 0.01$; Welch's t -test with Benjamini–Hochberg adjustment). **(D)** Total OxPL abundance by cluster vs. BODIPY C11 lipid peroxidation assay. Total OxPL intensity of each defined cluster (from Figure 4E) was calculated and transformed into Z score. Z score of each cluster is plotted (lines in shades of brown) together with Z score of the percentage of peroxidation-positive cells by BODIPY C11 staining (Figure 5C) (green line, also shown in Figure S6). Shaded area indicates SEM ($n = 3$) on all lines. Pearson correlation analysis was performed to assess the relationship between time-dependent changes in peroxidation-positive cells and total OxPL abundance in each cluster. Correlation coefficient (R) and BH-adjusted P -value of each correlation are shown ($**P < 0.01$; ns, non-significant).


Abstract Graphic



Supplementary Figures

Figure S1

A



B




Figure S1. System stability and reproducibility. **(A)** Intensities of deuterated internal standards in pooled samples throughout this study. Dot-and-whisker plot showing the normalized intensity of each deuterated internal standard. Each injection (individual dots) is shown with error bars representing mean \pm SEM ($n = 3$). Absolute mean intensity (Int; brown) and coefficient of variation (CV; blue) are included above each internal standard. Dashed lines indicate $\pm 10\%$ CV from the mean normalized intensity. **(B)** Retention time monitoring throughout this study. Retention time (Y-axis) of each deuterated internal standard is plotted against sequential injection order of the pooled sample (X-axis). CV of retention time is shown in each panel. Dashed lines indicate ± 0.05 min from the mean retention time of each internal standard.

Figure S2




Figure S2. Hydrogen-based Kendrick mass defect (H-KMD) plots of identified oxidized phospholipids and their corresponding non-oxidized precursor(s). The X-axis represents the chromatographic retention time, and the Y-axis represents the H-KMD, calculated by scaling the measured m/z to the nominal mass of hydrogen. Each data point represents an individual lipid species. Non-oxidized precursor lipids are shown in magenta, and oxidized lipids are shown in pink or purple. Shapes indicate different OxPL and precursor pairings. Circles are used when OxPLs and their corresponding precursors share identical fatty acyl compositions, whereas distinct precursors with fatty acyl compositions different from those of product OxPLs are represented by squares, diamonds, or triangles. Potential in-source fragmentation (ISF) products (removed from data analysis) are shown as inverted triangles in green.

Figure S3




Figure S3. Non-oxidized lipidomic profiles of Fenton and H₂O₂-only references. **(A)** Principal component analysis (PCA) on log₂-transformed normalized intensities of 715 common non-oxidized lipids identified in Fenton (dots in shades of red and grey) and H₂O₂-only (triangles in shades of blue and grey) references. Each data point represents one sample at a specific time point from either Fenton or H₂O₂-only references. **(B-C)** PCA on log₂-transformed normalized intensities of 715 non-oxidized lipids identified in Fenton (B) and 739 non-oxidized lipids identified in H₂O₂-only (C) references. Each data point represents one sample at a specific time point from either Fenton or H₂O₂-only references.

Figure S4




Figure S4. Cell viability with ML210 treatment. **(A)** Viability of KP4 cells treated with different concentrations of ML210 for 24 hours in the absence (magenta) or presence (brown) of ferrostatin-1 (Fer-1). Mean viability (dot) is presented together with error bars (\pm SEM) ($n = 6$). **(B)** Viability of KP4 cells treated with 10 μ M of ML210 at 6 different time points. Mean viability (dot) is presented together with error bars (\pm SEM) ($n = 3$).

Figure S5




Figure S5. BODIPY C11 lipid peroxidation assay by flow cytometry. **(A)** FACS gating strategy used to quantify peroxidation-positive cells by BODIPY C11 staining. Cells without ML210 treatment were used as negative gating controls to determine the gate for BODIPY C11 peroxidation-positive cells. **(B)** Histograms of BODIPY C11 staining intensity in PE-Texas Red channel (610/20 nm, representing non-oxidized form) by flow cytometry are shown for ML210-treated samples.

Figure S6

Overall total OxPL abundance vs. BODIPY C11




Figure S6. Overall total OxPL abundance vs. BODIPY C11 lipid peroxidation assay. Z scores of the percentage of peroxidation-positive cells by BODIPY C11 staining (green, also shown in Figure 5D) are plotted together with Z scores of total OxPL intensity (purple) in samples treated with ML210. Statistical significance at each time point was tested against 0 min control using Welch's *t*-test with Benjamini–Hochberg adjustment (ns = non-significant). Shaded areas indicate SEM (n = 3). Pearson correlation analysis was performed to assess the relationship between time-dependent changes in peroxidation-positive cells and total OxPL abundance. Correlation coefficient (*R*) and *P* value are shown.

Created by

Separation Workflow	2
Overall study design	2
Lipid extraction	2
Analytical platform	2
Quality control	2
Method qualification and validation	2
Reporting	3
Sample Descriptions	3
KP4 cells / Human / Cells	3
Lipid Class Descriptions	3
1) FA[M-H]- / Lipid identification	3
1) FA[M-H]- / Lipid quantification	3
2) DG[M+NH ₄]+ / Lipid identification	4
2) DG[M+NH ₄]+ / Lipid quantification	4
3) TG[M+NH ₄]+ / Lipid identification	4
3) TG[M+NH ₄]+ / Lipid quantification	5
4) PG[M-H]- / Lipid identification	5
4) PG[M-H]- / Lipid quantification	5
5) PI[M-H]- / Lipid identification	6
5) PI[M-H]- / Lipid quantification	6
6) PS[M-H]- / Lipid identification	6
6) PS[M-H]- / Lipid quantification	7
7) PE[M-H]- / Lipid identification	7
7) PE[M-H]- / Lipid quantification	8
8) LPE[M-H]- / Lipid identification	8
8) LPE[M-H]- / Lipid quantification	8
9) PE P[M+H]+ / Lipid identification	8
9) PE P[M+H]+ / Lipid quantification	9
10) PE O[M-H]- / Lipid identification	9
10) PE O[M-H]- / Lipid quantification	10
11) CL[M-H]- / Lipid identification	10
11) CL[M-H]- / Lipid quantification	10
12) PC[M+H]+ / Lipid identification	11
12) PC[M+H]+ / Lipid quantification	11
13) PC[M+HCOO]- / Lipid identification	11
13) PC[M+HCOO]- / Lipid quantification	12
14) LPC[M+H]+ / Lipid identification	12
14) LPC[M+H]+ / Lipid quantification	12
15) LPC[M+HCOO]- / Lipid identification	12
15) LPC[M+HCOO]- / Lipid quantification	13
16) PC O[M+H]+ / Lipid identification	13
16) PC O[M+H]+ / Lipid quantification	13
17) PC O[M+HCOO]- / Lipid identification	14
17) PC O[M+HCOO]- / Lipid quantification	14
18) EtherLPC-O (EtherLPC-P)[M+H]+ / Lipid identification	14
18) EtherLPC-O (EtherLPC-P)[M+H]+ / Lipid quantification	15
19) EtherLPE-O (EtherLPE-P)[M+H]+ / Lipid identification	15
19) EtherLPE-O (EtherLPE-P)[M+H]+ / Lipid quantification	15
20) OxPC-(<oxo>; <OH>; <OOH>; <2OH>) (molecular species level)[M+HCOO]- / Lipid identification	15
20) OxPC-(<oxo>; <OH>; <OOH>; <2OH>) (molecular species level)[M+HCOO]- / Lipid quantification	16
21) OxPC-(<COOH>) (molecular species level)[M-H]- / Lipid identification	16
21) OxPC-(<COOH>) (molecular species level)[M-H]- / Lipid quantification	17
22) OxPE-(<oxo>) (molecular species level)[M-H]- / Lipid identification	17
22) OxPE-(<oxo>) (molecular species level)[M-H]- / Lipid quantification	17
23) OxPS-(<oxo>; <OH>) (molecular species level)[M-H]- / Lipid identification	18
23) OxPS-(<oxo>; <OH>) (molecular species level)[M-H]- / Lipid quantification	18
24) OxLPC-(<oxo>; <OH>) (molecular species level)[M+HCOO]- / Lipid identification	18
24) OxLPC-(<oxo>; <OH>) (molecular species level)[M+HCOO]- / Lipid quantification	19
25) OxLPE-(<oxo>; <OH>) (molecular species level)[M-H]- / Lipid identification	19
25) OxLPE-(<oxo>; <OH>) (molecular species level)[M-H]- / Lipid quantification	19
26) OxPC-(<oxo>; <OH>; <OH,oxo>; <OH,oxo,OOH>; <2oxo,OOH>) (species level)[M+HCOO]- / Lipid identification	20
26) OxPC-(<oxo>; <OH>; <OH,oxo>; <OH,oxo,OOH>; <2oxo,OOH>) (species level)[M+HCOO]- / Lipid quantification	20
27) OxPC-(<COOH>;<OOH,COOH>) (species level)[M-H]- / Lipid identification	20
27) OxPC-(<COOH>;<OOH,COOH>) (species level)[M-H]- / Lipid quantification	21

28) OxPE-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$; $\langle\text{2OH,oxo}\rangle$; $\langle\text{2OH,OOH}\rangle$) (species level)[M-H] ⁻ / Lipid identification	21
28) OxPE-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$; $\langle\text{2OH,oxo}\rangle$; $\langle\text{2OH,OOH}\rangle$) (species level)[M-H] ⁻ / Lipid quantification	21
29) OxPG-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$) (species level)[M-H] ⁻ / Lipid identification	22
29) OxPG-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$) (species level)[M-H] ⁻ / Lipid quantification	22
30) OxPS-($\langle\text{oxo}\rangle$; $\langle\text{2oxo}\rangle$; $\langle\text{2OH}\rangle$) (species level)[M-H] ⁻ / Lipid identification	22
30) OxPS-($\langle\text{oxo}\rangle$; $\langle\text{2oxo}\rangle$; $\langle\text{2OH}\rangle$) (species level)[M-H] ⁻ / Lipid quantification	23
31) OxEtherPC-($\langle\text{OH}\rangle$) (species level)[M+HCOO] ⁻ / Lipid identification	23
31) OxEtherPC-($\langle\text{OH}\rangle$) (species level)[M+HCOO] ⁻ / Lipid quantification	23

Separation Workflow

Overall study design

Title of the study	A new method for the analysis of oxidized phospholipids		
Document creation date	04/23/2026	Principal investigator	Xiaoai Zhao
Institution	Yale University	Corresponding Email	Xiaoai.zhao@yale.edu
Is the workflow targeted or untargeted?	Untargeted	Clinical	No

Lipid extraction

Extraction method	2-phase system	pH adjustment	None
2-phase system	Folch	Special conditions	The antioxidant BHT was added in the extraction solution. Samples underwent intensive mixing and sonication at 4 °C.
Derivatization	Not applicable	Were internal standards added prior extraction?	Yes

Analytical platform

Ionization additives	Ammonium acetate, Formic acid	Number of separation dimensions	One dimension
Separation type 1	LC	Separation mode 1 (liquid)	RP
Detector	Mass spectrometer	MS type	Orbitrap
MS vendor	Thermo	Ion source	ESI
MS Level	MS ¹ , MS ²	Mass resolution for detected ion at MS ¹	High resolution
Resolution at m/z 200 at MS ¹	120000	Mass accuracy in ppm at MS ¹	2
Recording mode of raw data at MS ¹	Profile mode	Mass window for precursor ion isolation (in Da total isolation window)	1.2
Mass resolution for detected ion at MS ²	High resolution	Resolution at m/z 200 at MS ²	30000
Mass accuracy in ppm at MS ²	5	Recording mode of raw data at MS ²	Profile mode
Was/Were additional dimension/techniques used	No		

Quality control

Blanks	Yes	Type of Blanks	Extraction blank, Solvent blank, Internal standard blank
Quality control	Yes	Type of QC sample	Sample pool

Method qualification and validation

Method validation	Yes	Lipid recovery	No
Dynamic quantification range	No	Limit of quantitation (LOQ)/Limit of No detection (LOD)	
Precision	Yes	Accuracy	Yes
Guidelines followed	None		

Reporting

Are reported raw data uploaded into repository?	Yes	Link to repository / ID to entry	http://
Are metadata available?	Yes	Summary data	Quantification and identification data
Raw data upload	Yes		

Sample Descriptions

KP4 cells / Human / Cells

Storage and collection conditions	Available	Provided preanalytical information	Time to freeze, Storage time (month), Preservation method
Temperature handling original sample	Dry ice	Instant sample preparation	Yes
Time to freeze	between 2 and 5 min	Snap freezing in liquid N2	No
Storage temperature	-80 °C	Storage time (month)	0.5
Additives	None		

Lipid Class Descriptions

1) FA[M-H]- / Lipid identification

Lipid class	FA	MS Level for identification	MS ¹
Identification level	Species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ¹ verified by standard	Yes
Background check at MS ¹	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes		

1) FA[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
FA(18:1(d17))		FA subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold

Normalization to reference	No	Lipid Quantification Software	MS-DIAL
Batch correction	No		

2) DG[M+NH4]⁺ / Lipid identification

Lipid class	DG	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+NH4] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+NH4] ⁺
Fragments for identification			
Fragment name			
-(H2O+NH3,35)			
-FA1(-H)-(H2O+NH3)			
-FA2(-H)-(H2O+NH3)			
Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

2) DG[M+NH4]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
DG(15:0_18:1(d7))		DG subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

3) TG[M+NH4]⁺ / Lipid identification

Lipid class	TG	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+NH4] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+NH4] ⁺
Fragments for identification			
Fragment name			
-FA1(+HO)-(NH3)			
-FA2(+HO)-(NH3)			

-FA3(+HO)-(NH3)

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

3) TG[M+NH4]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
TG(15:0_18:1(d7)_15:0)		TG subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

4) PG[M-H]⁻ / Lipid identification

Lipid class	PG	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H] ⁻
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO] ⁻
Fragments for identification			
Fragment name			
FA1(+O)			
FA2(+O)			
GP(153)			

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	No	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

4) PG[M-H]⁻ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			

Internal standard	Endogenous subclass
PG(15:0-18:1(d7))	PG subclass

Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

5) PI[M-H]- / Lipid identification

Lipid class	PI	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-

Fragments for identification

Fragment name
FA1(+O)
FA1(+O)
HG(PI, 241)

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

5) PI[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
--------------	-----	-----------------------------	-----------------

Internal lipid standard(s) MS¹

Internal standard	Endogenous subclass
PI(15:0_18:1(d7))	PI subclass

Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

6) PS[M-H]- / Lipid identification

Lipid class	PS	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-

Fragments for identification

Fragment name
FA1(+O)
FA2(+O)
GP(153)

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

6) PS[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PS(15:0_18:1(d7))		PS subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

7) PE[M-H]- / Lipid identification

Lipid class	PE	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-

Fragments for identification

Fragment name
FA1(+O)
FA2(+O)
HG(PE,196)

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

7) PE[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PE(15:0_18:1(d7))		PE subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

8) LPE[M-H]- / Lipid identification

Lipid class	LPE	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			
Fragment name			
FA1(+O)			
HG(PE,196)			
Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

8) LPE[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
LPE(18:1(d7))		LPE subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

9) PE P[M+H]⁺ / Lipid identification

Lipid class	PE P	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+H] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+H] ⁺
Fragments for identification			
Fragment name			
-HG(PE,141)			
FA2+(C3H5O2)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

9) PE P[M+H]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PE(15:0_18:1(d7))		EtherPE(P) subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

10) PE O[M-H]⁻ / Lipid identification

Lipid class	PE O	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H] ⁻
Isotope correction at MS ¹	No	MS ² adduct	[M-H] ⁻
Fragments for identification			
Fragment name			
FA2(+O)			
HG(PE,196)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

10) PE O[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PE(15:0_18:1(d7))		Ether PE subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

11) CL[M-H]- / Lipid identification

Lipid class	CL	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			
Fragment name			
FA1(+O)			
FA2(+O)			
FA3(+O)			
FA4(+O)			
HG(CL,153)			
Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

11) CL[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
CL(18:2_18:2_18:2_18:2(d5))		CL subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

12) PC[M+H]⁺ / Lipid identification

Lipid class	PC	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+H] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+H] ⁺
Fragments for identification			
Fragment name			
HG(PC,184)			
Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

12) PC[M+H]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PC(15:0_18:1(d7))		PC subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

13) PC[M+HCOO]⁻ / Lipid identification

Lipid class	PC	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+HCOO] ⁻
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO] ⁻
Fragments for identification			
Fragment name			
FA1(+O)			
FA2(+O)			
HG(PC,224)			
Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding

Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes
--	-----	--------------------------------	-----

13) PC[M+HCOO]- / Lipid quantification

Quantitative	No	Normalization to reference	No
Batch correction	No		

14) LPC[M+H]⁺ / Lipid identification

Lipid class	LPC	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+H] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+H] ⁺

Fragments for identification

Fragment name

HG(PC,184)

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

14) LPC[M+H]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			

Internal standard

LPC(18:1(d7))

Endogenous subclass

LPC subclass

Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

15) LPC[M+HCOO]- / Lipid identification

Lipid class	LPC	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+HCOO]-
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO]-

Fragments for identification

Fragment name

HG(PC,224)

FA1(+O)

Isotope correction at MS ²	No	MS ¹ verified by standard	Yes
MS ² verified by standard	Yes	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

15) LPC[M+HCOO]- / Lipid quantification

Quantitative	No	Normalization to reference	No
Batch correction	No		

16) PC O[M+H]⁺ / Lipid identification

Lipid class	PC O	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+H] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+H] ⁺
Fragments for identification			

Fragment name

HG(PC,184)

Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	Yes
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

16) PC O[M+H]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			

Internal standard

PC(15:0_18:1(d7))

Endogenous subclass

EtherPC-O subclass

Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

17) PC O[M+HCOO]- / Lipid identification

Lipid class	PC O	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+HCOO]-
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO]-
Fragments for identification			
Fragment name			
FA2(+O)			
Head group (C7H15N1O5P-, 224.0693)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

17) PC O[M+HCOO]- / Lipid quantification

Quantitative	No	Normalization to reference	No
Batch correction	No		

18) EtherLPC-O (EtherLPC-P)[M+H]+ / Lipid identification

Lipid class	EtherLPC-O (EtherLPC-P)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+H]+
Isotope correction at MS ¹	No	MS ² adduct	[M+H]+
Fragments for identification			
Fragment name			
HG(PC,184)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	Yes

18) EtherLPC-O (EtherLPC-P)[M+H]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
LPC(18:1(d7))		EtherLPC-O (EtherLPC-P) subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

19) EtherLPE-O (EtherLPE-P)[M+H]⁺ / Lipid identification

Lipid class	EtherLPE-O (EtherLPE-P)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+H] ⁺
Isotope correction at MS ¹	No	MS ² adduct	[M+H] ⁺
Fragments for identification			
Fragment name			
NL of C ₃ H ₁₀ N ₅ O ₅ P and NL of C ₃ H ₁₀ N ₄ O ₄ P			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	No

19) EtherLPE-O (EtherLPE-P)[M+H]⁺ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
LPE(18:1(d7))		EtherLPE-O (EtherLPE-O) subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	No	Lipid Quantification Software	MS-DIAL
Batch correction	No		

20) OxPC-(<oxo>; <OH>; <OOH>; <2OH>) (molecular species level)[M+HCOO]⁻ / Lipid identification

Lipid class	OxPC-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$) (molecular species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+HCOO]-
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO]-
Fragments for identification			
Fragment name			
FA1(+O)			
oxidized FA2(+O), or oxidized FA2(+O) with water loss			
HG(PC,224)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

20) OxPC-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$) (molecular species level) [M+HCOO]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PC(15:0_18:1(d7))		OxPC subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

21) OxPC-($\langle\text{COOH}\rangle$) (molecular species level) [M-H]- / Lipid identification

Lipid class	OxPC-($\langle\text{COOH}\rangle$) (molecular species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			
Fragment name			
FA1(+O)			
oxidized FA2(+O), or oxidized FA2(+O) with water loss			
HG(PC,224)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No

Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

21) OxPC-($\langle\text{COOH}\rangle$) (molecular species level)[M-H]- / Lipid quantification

Quantitative	No	Normalization to reference	No
Batch correction	No		

22) OxPE-($\langle\text{oxo}\rangle$) (molecular species level)[M-H]- / Lipid identification

Lipid class	OxPE-($\langle\text{oxo}\rangle$) (molecular species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-

Fragments for identification

Fragment name

FA1(+O)

oxidized FA2(+O), or oxidized FA2(+O) with water loss

HG(PE,196)

Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

22) OxPE-($\langle\text{oxo}\rangle$) (molecular species level)[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PE(15:0_18:1(d7))		OxPE subclass	

Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

23) OxPS-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)[M-H]- / Lipid identification

Lipid class	OxPS-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			
Fragment name			
FA1(+O)			
oxidized FA2(+O), or oxidized FA2(+O) with water loss			
GP(153)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

23) OxPS-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PS(15:0_18:1(d7))		OxPS subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

24) OxLPC-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)[M+HCOO]- / Lipid identification

Lipid class	OxLPC-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M+HCOO]-
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO]-
Fragments for identification			
Fragment name			
oxidized FA1(+O), or oxidized FA1(+O) with water loss			
HG(PC,184)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No

Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

24) OxLPC-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)[M+HCOO]- / Lipid quantification

Quantitative	No	Normalization to reference	No
Batch correction	No		

25) OxLPE-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)[M-H]- / Lipid identification

Lipid class	OxLPE-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Molecular species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-

Fragments for identification

Fragment name

oxidized FA1(+O), or oxidized FA1(+O) with water loss

HG(PE,196)

Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	No	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

25) OxLPE-($\langle\text{oxo}\rangle$; $\langle\text{OH}\rangle$) (molecular species level)[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			

Internal standard

LPE(18:1(d7))

Endogenous subclass

OxLPE subclass

Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	No
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

26) OxPC-($\langle \text{oxo} \rangle$; $\langle \text{OH} \rangle$; $\langle \text{OH,oxo} \rangle$; $\langle \text{OH,oxo,OOH} \rangle$; $\langle 2\text{oxo,OOH} \rangle$) (species level)[M+HCOO]⁻ / Lipid identification

Lipid class	OxPC-($\langle \text{oxo} \rangle$; $\langle \text{OH} \rangle$; $\langle \text{OH,oxo} \rangle$; $\langle \text{OH,oxo,OOH} \rangle$; $\langle 2\text{oxo,OOH} \rangle$) (species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Species level	MS ¹ adduct	[M+HCOO] ⁻
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO] ⁻
Fragments for identification			
Fragment name			
FA1(+O)			
HG(PC,224)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	Yes	Nomenclature for fragment ions	No

26) OxPC-($\langle \text{oxo} \rangle$; $\langle \text{OH} \rangle$; $\langle \text{OH,oxo} \rangle$; $\langle \text{OH,oxo,OOH} \rangle$; $\langle 2\text{oxo,OOH} \rangle$) (species level)[M+HCOO]⁻ / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PC(15:0_18:1(d7))		OxPC subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

27) OxPC-($\langle \text{COOH} \rangle$; $\langle \text{OOH,COOH} \rangle$) (species level)[M-H]⁻ / Lipid identification

Lipid class	OxPC-($\langle \text{COOH} \rangle$; $\langle \text{OOH,COOH} \rangle$) (species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Species level	MS ¹ adduct	[M-H] ⁻
Isotope correction at MS ¹	No	MS ² adduct	[M-H] ⁻
Fragments for identification			
Fragment name			
FA1(+O)			
HG(PC,224)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No

Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

27) OxPC-($\langle\text{COOH}\rangle$; $\langle\text{OOH},\text{COOH}\rangle$) (species level)[M-H]- / Lipid quantification

Quantitative	No	Normalization to reference	No
Batch correction	No		

28) OxPE-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$; $\langle\text{2OH},\text{oxo}\rangle$; $\langle\text{2OH},\text{OOH}\rangle$) (species level)[M-H]- / Lipid identification

Lipid class	OxPE-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$; $\langle\text{2OH},\text{oxo}\rangle$; $\langle\text{2OH},\text{OOH}\rangle$) (species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			

Fragment name

FA1(+O)

HG(PE,196)

Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interferece confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

28) OxPE-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$; $\langle\text{2OH}\rangle$; $\langle\text{2OH},\text{oxo}\rangle$; $\langle\text{2OH},\text{OOH}\rangle$) (species level)[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard	PE(15:0_18:1(d7))	Endogenous subclass	OxPE subclass
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

29) OxPG-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$) (species level)[M-H]- / Lipid identification

Lipid class	OxPG-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$) (species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			
Fragment name			
FA1(+O)			
GP(153)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

29) OxPG-($\langle\text{oxo}\rangle$; $\langle\text{OOH}\rangle$) (species level)[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PG(15:0-18:1(d7))		OxPG subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

30) OxPS-($\langle\text{oxo}\rangle$; $\langle 2\text{oxo}\rangle$; $\langle 2\text{OH}\rangle$) (species level)[M-H]- / Lipid identification

Lipid class	OxPS-($\langle\text{oxo}\rangle$; $\langle 2\text{oxo}\rangle$; $\langle 2\text{OH}\rangle$) (species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Species level	MS ¹ adduct	[M-H]-
Isotope correction at MS ¹	No	MS ² adduct	[M-H]-
Fragments for identification			
Fragment name			
FA1(+O)			
GP(153)			
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No

Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

30) OxPS-($\langle\text{oxo}\rangle$; $\langle 2\text{oxo}\rangle$; $\langle 2\text{OH}\rangle$) (species level)[M-H]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PS(15:0_18:1(d7))		OxPS subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold
Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		

31) OxEtherPC-($\langle\text{OH}\rangle$) (species level)[M+HCOO]- / Lipid identification

Lipid class	OxEtherPC-($\langle\text{OH}\rangle$) (species level)	MS Level for identification	MS ¹ , MS ²
Identification level	Species level	MS ¹ adduct	[M+HCOO]-
Isotope correction at MS ¹	No	MS ² adduct	[M+HCOO]-
Fragments for identification			
Fragment name			
	oxidized FA2(+O), or oxidized FA2(+O) with water loss		
	HG(PC,224)		
Isotope correction at MS ²	No	MS ¹ verified by standard	No
MS ² verified by standard	No	Background check at MS ¹	No
Background check at MS ²	No	Did you presume assumptions for identification?	No
Limit of detection	Signal threshold	RT verified by standard	No
Separation of isobaric/isomeric interference confirmed	Yes	Model for separation prediction	Yes
Lipid Identification Software	MS-DIAL	Data manipulation	Smoothing, Centroiding
Nomenclature for intact lipid molecule	No	Nomenclature for fragment ions	No

31) OxEtherPC-($\langle\text{OH}\rangle$) (species level)[M+HCOO]- / Lipid quantification

Quantitative	Yes	MS Level for quantification	MS ¹
Internal lipid standard(s) MS ¹			
Internal standard		Endogenous subclass	
PC(15:0_18:1(d7))		OxEtherPC subclass	
Type of quantification	Internal standard amount	Response correction	No
Type I isotope correction	No	Limit of quantification	Signal threshold

Normalization to reference	Yes	Lipid Quantification Software	MS-DIAL
Batch correction	No		
